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CHAPTER 1: OVERVIEW OF PROSTATE CANCER AND OBESITY
Introduction
Prostate cancer (PCa) is one of the most commonly diagnosed cancers in men [1].
Because this disease is normally associated with aging, long-term exposure to environmental
agents, chronic inflammation, genetic alterations, and defective androgen receptor signaling
have all been speculated as causal factors in tumor initiation and support [2, 3]. Within the last
decade, new research has suggested that increased adiposity represents another important
factor contributing to overall poor prognosis, shorter time to disease recurrence, and increased
mortality [4]. However, the data that directly link adiposity and tumor initiation and metastasis
have so far been conflicting [5]. A meta-analysis of 17 cohort studies reported that obese men
have increased risk of aggressive prostate cancer and mortality compared to normal weight
men [5]. The same study also noted that there were mixed conclusions linking obesity with
tumor initiation. A retrospective study of 2210 patients that received radical prostatectomy
revealed no significant differences in disease progression with increased body mass index (BMI)
[6].

Other studies reported a strong correlation between obesity and benign prostatic

hyperplasia (BPH) [7, 8]. Clearly, conflicting clinical findings warrant further investigation to
determine the driving forces that promote PCa aggressiveness in patients.

The studies

presented here examined the effects of bone marrow adiposity on inflammation and metastatic
tumor growth in bone with the hope of uncovering novel mechanisms associated with disease
progression.
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1.1 Tumor Dissemination out of the Prostate to Bone
During normal development, prostate cells rely on androgen signaling to mediate cell
growth and function [9]. However, defective androgen signaling is often the result of genetic
mutations that accumulate with repeated environmental exposures and factors such as
infection, diet, environmental carcinogens as well as race, family history and age [10]. The road
from prostate cancer initiation to androgen independence and advanced disease is lengthy and
if PCa is detected early, the 5-year survival is almost 100% [11]. The first stage of prostate
cancer is enlargement of the prostate resulting from augmented androgen signaling, or benign
prostatic hyperplasia (BPH) [12]. However, it is important to keep in mind that men with
enlarged prostates do not always go on to develop cancer [12]. If the disease progresses to
form prostatic intraepithelial neoplasia (PIN), abnormal growths form around prostatic ducts
[13]. Studies demonstrated that cells in PIN lesions acquire several genetic alterations including
telomere shortening, overexpression of oncogenes, and expression of the TMPRSS2-ERG fusion
gene [13].

Eventually, tumors progress to prostate adenocarcinoma, but they are still

responsive to androgens in a majority of patients [14].

The first line of treatment for such

cancers is androgen ablation and tumors often shrink because androgen withdrawal disrupts
the unequal balance between cell proliferation and apoptosis [15].

However, this initial

response is often followed by the development of androgen-independent signaling resulting in
uncontrolled growth and eventual resistance to androgen deprivation and classic
chemotherapy [16].
Androgen-independent tumor growth has been an area of intense research in attempts
to understand the molecular mechanisms associated with disease recurrence [17, 18] and to
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develop novel therapeutics to treat androgen-independent PCa [19, 20]. Ineffective therapies
result in disease recurrence and more aggressive disease [14]. Evidence has demonstrated that
gain-of-function mutations in tumor cells promote anchorage-independent growth and stemlike characteristics that support dissemination out of the prostate and into the circulatory and
lymphatic systems [21]. Several studies have tried to determine why prostate cancer prefers
certain anatomical sites over others for secondary growth. A large post-mortem study of 1,589
patients with prostate cancer reported that 35% of patients had some form of metastasis and
90% of those examined had tumor lesions in bone compared to other common metastatic sites
such as liver (25%) and lung (46%) [22]. Early ground-breaking work by Roy et al. demonstrated
that prostate cancer cells cultured with bone marrow conditioned media exhibited extensive
proliferation compared to cells exposed to conditioned media from other common metastatic
sites [23]. Moreover, these proliferative effects were stimulated by tumor-supplied
hematopoietic factors fibroblast growth factor (FGF), GM-CSF, as well as transforming growth
factors α and β [23].

Since these early studies, several groups have identified other

chemotactic factors that stimulate prostate tumor homing and seeding in bone including
growth factors [24], stromal factors [25] and cytokines [26]. As more studies uncover the roles
of the bone microenvironment in tumor metastasis, we now realize tumor cells have a
supporting cast that aids in tumor progression.
1.2 Contributions of Adipocytes and Macrophages to Prostate Tumor Progression
During the aging process the bone is continuously remodeled, but with time the density
of trabecular bone is decreased resulting in reduced bone mass and osteoporosis [27].
‘Inflamm-aging’ or chronic low-grade inflammation is an underlying consequence of reduced
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bone formation associated with age and it results in production of inflammatory factors, such
as IL-6, TNF-α, and IL-1β [28]. Interestingly, these factors are direct or indirect stimulators of
osteoclastogenesis and chemoattractants for prostate cancer cells [28-30]. The preferred sites
for prostate tumor growth in the bone is the axial skeleton known to be under active
remodeling [31]. Therefore, accelerated bone remodeling and chronic inflammation may be the
perfect combination tumor cells need to thrive outside the prostate. Although disseminated
tumor cells have some innate ability to enhance metabolic functions needed for accelerated
growth, they also recruit stromal cells to aid in these processes including bone marrow
adipocytes and macrophages. Together, they provide the factors necessary for tumor growth,
invasion, immune evasion, angiogenesis that often lead to eventual patient mortality [32].
1.2.1 Bone marrow adipocytes
Tumor promotion and aggressive disease have been well-linked with visceral adiposity
[33]; however, little is known concerning the roles of bone marrow adiposity in progression of
metastatic disease. With age and obesity, a shift in bone marrow composition occurs toward
formation of fat cells, parallel with increased osteoclast function and resulting bone loss [34,
35]. In fact, the bone marrow of newborn infants is composed primarily of hematopoietic cells
whereas adult bone marrow contains as much as 7% of total body fat [36]. Other factors that
can induce marrow adiposity in addition to obesity and age include alcoholism, inactivity,
anorexia nervosa, and paralysis [37]. This is of importance, as evidence has suggested that
bone marrow adipocytes are a unique subset of fat different from other depots, particularly in
their distribution and fatty acid composition [38, 39]. Since these fat cells produce potent
signaling molecules such as adiponectin and leptin, hormones, cytokines and growth factors,
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they are capable of modulating bone metabolism [36, 40].
Magnetic resonance imaging of the skeleton demonstrated that fat is unequally
distributed throughout bone [41]. The differential accumulation of fat in the proximal and
distal region of long bones may have functional roles in normal physiology and metastatic bone
disease. Some studies suggest that proximal fat may be supplying energy and adipokines
necessary for bone remodeling while adipocytes in the less actively remodelled distal bone may
be inactive cells that hinder new bone formation [40]. New evidence is beginning to uncover a
possible role of bone marrow adiposity and tumor progression in bone (as reviewed in [42]) .
Therefore, it is important to understand how adipocytes promote tumor homing to bone and
what factors aid in tumor growth in the skeletal microenvironment.
Adipocytes secrete lipids that modulate cell signaling pathways of different cell types
and may aid in altering the bone milieu in favor of tumor progression. Our lab previously
reported that prostate cancer cells readily take up lipids from bone marrow adipocytes and
long-term exposure to adipocyte-derived factors leads to increased growth and invasiveness
[43]. Bone marrow adiposity has also been shown to evoke cancer-promoting effects in
multiple myeloma. Studies demonstrated that myeloma cells are attracted to adipocytes and
factors released by this interaction promote tumor cell proliferation and migration while
inhibiting apoptosis [44]. Together, these data suggest that tumor cells not only have the
capabilities of drawing lipids from surrounding adipocytes, but they also can utilize factors that
stimulate lipid formation to supply their own fat stores.
In addition to lipids, tumor cells also depend on adipocyte-supplied adipokines and
cytokines to drive tumor growth and survival. One such well-studied adipokine is leptin, a
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hormone that responds to changes in nutritional status and energy utilization [45].
Interestingly, reduced expression of leptin is correlated with obesity, abnormal development of
long bones, and cancer [42, 46, 47]. Leptin stimulates expression of genes associated with
epithelial-to-mesenchymal transition (EMT) [48, 49] and estrogen-independent cell growth in
breast cancer [49]. It promotes tumor growth, migration, and invasion in prostate and ovarian
cancers as well [50-52]. Leptin is also important in prostate tumor growth in bone; however,
some data suggest that it does this indirectly through leptin-stimulated bone resorption [53,
54]. Others suggest that this adipokine exerts mitogenic effects in prostate cancer cells directly
by activating MAPK [55] and JNK pathways [56]. Although the specific functions of leptin are
still being investigated, these data demonstrate that tumor cells rely of adipocyte-supplied
factors for tumor growth and metastasis.
Adiponectin, another well-characterized adipokine, is also expressed in adipocytes and
functions with leptin to regulate energy utilization and insulin sensitivity [57]. Interestingly, this
protein also serves in bone remodeling by inhibiting osteoblast differentiation and subsequent
bone formation [58]. Adiponectin is expressed at much higher levels in marrow adipose tissue
compared to other fat depots and is secreted in response to caloric restriction, particular
anorexia and cancer treatment [59, 60]. Levels of secreted adiponectin have been extensively
investigated in the context of tumorigenic activation or inhibition; however, studies have
demonstrated that its roles may be unique in different malignancies [61]. Reports show that
tissue isolated from patients with prostate cancer expressed lower levels of adiponectin
compared to benign prostatic hyperplasia tissue samples, result associated with increased
cellular proliferation, EMT, and overall poor prognosis [62]. Other studies have reported similar
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findings demonstrating that low adiponectin levels are also linked with increased grade of
disease in prostate cancer patients and may serve as a marker of progression [63]. Despite
compelling evidence that adiposity is associated with tumor progression, the role of individual
adipokines in these processes has yet to be fully investigated.
1.2.2 Bone marrow macrophages and inflammation
Inflammation in bone plays an equally important role in tumor progression as adiposity.
As previously mentioned, adipocytes secrete factors associated with chronic inflammation [42];
however, adipocytes may also work in concert with resident bone marrow macrophages
(BMMs) to enhance inflammation that contributes to metastatic disease. BMM numbers,
phenotype and function are influenced by changes in bone remodeling [64], increased adiposity
[65], as well as tumor-driven alterations in the bone marrow milieu [66]. Because of the
overwhelming exposure to a number of environmental signals, macrophages only respond to
particular factors to prevent continuous inflammation associated with chronic inflammatory
disorders [67].

Macrophages also have inherent programming that prevents them from

attacking host tissue and resulting in autoimmune disorders such as Crohn’s disease and
rheumatoid arthritis [67]. This ability for programmed response may present a difficult and
unique challenge for PCa therapy because, as studies have shown, macrophages can be
recruited by tumor cells to aid in angiogenesis and cell survival instead of targeting malignant
cells for phagocytosis [68].
To add to the complexity of the immune response in bone, in addition to serving as
resident inflammatory mediators, BMMs, also aid in bone remodelling events. Specifically, they

8

contribute to recalcification to maintain homeostatic bone remodeling and secrete factors that
aid in osteoblastogenesis [69]. Studies utilizing macrophage Fas-induced apoptosis (MAFIA)
mouse model of macrophage depletion demonstrated that mice devoid of macrophages
develop an osteopetrotic bone phenotype [70]. These mice also express lower levels of bone
remodeling genes and have reduced bone volume compared to normal controls [70]. Because
BMMs have diverse roles in bone, they are among the most manipulated stromal cell type that
aids in immune evasion, angiogenesis, and tumor promotion [71].

Recent attention has

focused on the roles of bone marrow adiposity and adipose-associated macrophages in chronic
inflammation, metabolic alterations, and osteolysis [72, 73]. An area of intense investigation in
tumor-driven inflammatory response is the ability of tumors to alter the behavior of
macrophages to aid in tumor progression: specifically, phenotypic switching from a tumoricidal
M1 to tumorigenic M2 macrophage phenotype [74, 75].
1.2.2 M1 and M2 Macrophages
M1 macrophages are activated by interferon-γ (IFN-γ) and foreign bacterial antigens and
produce potent anti-microbial factors that promote bacterial cell death [76]. They are generally
characterized by expression of cell surface proteins and cytokines such nitric oxide synthase-2
(NOS-2), tumor necrosis factor α (TNFα), IL-12, and IL-23 and their accepted function is to
initiate the Th1 anti-tumorigenic immune response [76, 77]. Particularly, TNFα can sensitize
prostate, gastric, and lung cancers to chemotherapy agents, making it a potent driver of
immune-mediated cancer death [78]. On the other end of the spectrum, M2 macrophages
produce factors that promote wound healing, cell proliferation, and ultimately conclude the
inflammatory response [79]. These cells are characterized by the expression of arginase-1,
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mannose receptor, and CD163 among other markers and they mediate a T-helper 2
inflammatory response that counteracts the T-helper 1 M1 macrophage response [79, 80]. M2
macrophages have been positively associated with increased BMI and have similar molecular
characteristics to tumor-associated macrophages, suggesting that adiposity can promote
macrophage phenotype switching [81]. This evidence may provide a valuable link between
aggressive disease, inflammation, and adiposity in order to develop preventative measures to
slow disease progression.
In addition to interactions with adipocytes, macrophages can also communicate with
tumor cells to promote tumor growth and progression. In fact, patients treated with androgen
deprivation therapy show surprisingly significant infiltration of tumor-associated macrophages
into the prostate, event that has been associated with disease recurrence [82]. Reports
suggested this influx is mediated by CCL2 signaling as the number of macrophages in the
prostate can be reduced using an antagonist to the CCL2 receptor [82]. This suggests the
importance of macrophage involvement in tumor progression. Notably, CCL2 is known to be
secreted by tumor cells, promotes macrophage skewing from M1 to M2 phenotype to facilitate
growth and progression, and may account for reduced poor prognosis [83].
The ability of tumor cells to overcome obstacles and grow efficiently in the primary site
is particularly challenging in the secondary, complex microenvironments such as bone.
Vascularization is one of the key components that tumor cells must acquire to effectively
colonize in bone. Indeed, upon intratibial injection of prostate cells into canine model increased
vascularity of tumor bone was observed compared to control bone, and interestingly CD68 +
macrophages lined the periphery of the tumor aiding in bone remodeling and tumor outgrowth
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[84]. Proteolysis and matrix degradation are additional factors aiding in tumor progression in
bone. Specifically, cathepsin K (CTSK), a bone remodeling cysteine protease that degrades
collagen I plays a role in tumor growth and inflammation in bone marrow [85], and is one of the
critical factors in bone marrow macrophage-derived inflammation [86]. Studies in our lab have
shown that macrophages that express CTSK infiltrate prostate tumors more efficiently than
CTSK knockout macrophages resulting in reduced inflammatory response and tumor growth
[86].
Other factors with promoting effects on tumor growth in bone include monocyte
chemoattractant protein-1 (MCP-1) and cyclooxygenase-2 (COX-2). PC3 prostate tumor cells
overexpressing MCP-1 injected intravenously into SCID mice display an accelerated rate of
metastatic bone lesion formation due to the recruitment of resident macrophages in bone [87].
Cyclooxygenase-2, an inducible protein implicated in normal and tumor-induced inflammatory
response, was shown to be highly expressed by macrophages and to affect bone metabolism by
altering prostaglandin E2 (PGE2) synthesis and macrophage migration through cooperation with
CCL2 [as reviewed in [42]]. Indeed, nude mice injected intratibially with PC3 cells lacking the
functional receptor for PGE2, E-prostanoid receptor had reduced tumor burden, more intact
bone, and decreased production of COX2, IL-1β, and IL-6 cytokines [88], likely due to the
disruption of prostate tumor paracrine interactions with inflammatory mediators in the bone.
Collectively, these findings suggest that the supportive cells in the tumor microenvironment are
clearly playing critical roles in tumor seeding and metastasis and more directed studies
investigating these specific interactions may prove important for drug development and
modulating the immune response to tumoricidal attacks.
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1.3 Bone Remodeling and Metastasis
Tumor metastasis to bone has plagued mankind since the beginning of time. The oldest
recorded evidence of bone metastasis dates back circa 1200 BC based on the remains of an
ancient Egypt male that presented with osteolytic bone lesions in vertebrae pelvis, and long
bones [89]. The bone tends to be a preferential site of metastasis for cancers of the prostate,
breast, uterus, bladder, kidney, lung, and thyroid [8]. There have been many hypotheses why
these cancers spread to a site that is very rigid in nature and hard to colonize due to its
naturally hypoxic state. Although there has been a lot of progress in understanding the
attraction of prostate tumor cells to the bone, the role of bone microenvironment in supporting
the progression of metastatic cells in the skeleton is not well-understood. Once the tumor cells
invade into bone prostate cancer becomes incurable. Therefore, it is important to understand
the function of bone remodeling cells and the mechanisms used to promote bone turnover and
thrive in bone.
1.3.1 Normal Bone Remodeling
Normal bone remodeling is a complex process that involves the synchronous effort of
cytokines, growth factors, proteases and various cell types. The skeletal remodeling machinery
is made up of three major cell types: osteoblasts, osteoclasts, and osteocytes. Osteoblasts are
bone forming cells derived from mesenchymal stem cells, as are adipocytes, chondrocytes
(collagen-forming cells) and myocytes (muscle cells) [90]. Once osteoblasts have differentiated,
a fraction of them become osteocytes by being enclosed in the matrix they secrete which
ultimately forms hardened bone [91]. The role of osteocytes in the regulation of bone health
has recently become an area of more intense investigation and studies have uncovered the
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critical role of this cell type in initiating and orchestrating bone remodeling. In response to
changes in mechanical loads, osteocytes release prostatglandin E 2, nitric oxide, COX2, as well as
insulin growth factor-1 to activate osteoblasts that line the bone to promote secretion of bone
matrix [91]. Conversely, these cells also have the ability to prevent bone remodeling namely by
the expression and secretion of sclerostin, a glycoprotein that inhibits the formation of cortical
bone and dysregulated bone mineralization [92]. Notably, sclerostin expression is enhanced as
a result of increased inflammation and activation of NF-κB and tumor necrosis factor alpha
(TNF-α), resulting in reduced bone formation, increased receptor activator of nuclear factor
kappa-B ligand (RANKL), and accelerated bone resorption [93].
Both osteoblasts and osteocytes function in concert with bone degrading osteoclasts,
which are derived from hematopoietic stem cells similarly to immune cells such as T cells, B
cells, natural killer cells, and macrophages [94]. Osteoclasts are located near the surface of the
bone and they degrade old or damaged tissue. Their differentiation occurs by the fusion of
monocytes followed by the induction by haematopoietic factors macrophage-colony
stimulating factor (MCF) and RANKL, both of which are required for formation of mature
osteoclasts [95, 96]. During bone degradation, osteoclasts communicate with osteoblasts to
stimulate the production of new bone matrix through several signaling factors. Complement
component 3a (C3a) was identified as a factor secreted by mature osteoclasts that stimulates
osteoblast differentiation and increased bone turnover both in vitro and in vivo.
Osteoblastogenesis was significantly reduced when C3a was knocked down in osteoclasts or the
C3a receptor on osteoblasts was blocked utilizing a receptor antagonist [97]. Transforming
growth factor-β1 (TGF-β1) is another factor highly secreted by osteoclasts actively degrading
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bone matrix [98]. Studies have demonstrated that TGF-β1 supports the migration of bone
marrow stromal cells to sites of active bone remodeling by triggering downstream SMAD2/3
pathway, formation of osteoblasts and increased bone mineral density [99].
Once osteoblasts are activated, they release both non-collagen components (e. g.,
osteopontin, alkaline phosphatase, osteonectin), mineral components such as hydroxyapatite
and magnesium that provide tensile strength, and collagen components including collagen I
(most abundant in bone) and IV (very low amounts detected) that aid in plasticity [100].
Osteoblasts depend on the expression of several pro-osteoblastic proteins for effective
production of these factors. Studies have demonstrated that knockdown of fibroblast growth
factor-2 partially inhibits osteoblast differentiation in vitro [101]. In vivo studies verified that
FGF-2 null mice had reduced trabecular bone density and reduced osteoblast differentiation
[101]. Other studies have implicated other classical pathways that stimulate osteoblastogenesis
such as ERK and AKT signaling while hepatocyte growth factor/c-MET signaling abrogates these
effects [102] and this may prove important depending on changes in the bone
microenvironment resulting from age, disease, and inflammation.
Bone is a dynamic organ that changes with aging, physical activity, weight, and diet.
Studies have shown that bone marrow adiposity in particular affects bone function by
promoting osteoclastogenesis via stimulating the pre-osteoblasts to secrete higher levels of
RANKL while repressing genes associated with osteoblastogenesis such as RUNX2, osteocalcin,
and alkaline phosphatase [103]. Other studies have linked enhanced osteoclastogenesis and
accelerated bone resorption with induction of hypoxia. This is specifically evident when precursor cells are cultured in hypoxic conditions and these effects are partly driven by activation
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of hypoxia-inducible factor alpha (HIF1α) and autophagy pathways [104]. Indeed inhibition of
autophagy reduces both HIF1α expression and osteoclast formation suggesting that osteoclasts
utilize this mechanism when oxygen levels are reduced [104]. Recent evidence further suggests
that HIF1α induces vascular endothelial growth factor (VEGF), a factor recently implicated as an
alternate protein that stimulates osteoclast fusion independent of MCSF [105]. Understanding
the involvement of the abovementioned pathways in bone may prove important depending on
changes in the bone microenvironment resulting from age, disease, and inflammation.
1.3.2 Modifications to Bone in Tumor Metastasis
Tumor-driven changes in bone morphology vary upon the type of tumor. There are
three types of lesions that can form in bone as a result of metastatic disease: osteolytic,
osteoblastic, and mixed lesions. Osteolytic bone lesions are the result of overactive osteoclastmediated bone degradation found mostly in lung [106], thyroid [107], kidney [108] and breast
[109] metastases. Osteoblastic lesions are formed in prostate cancer and are characterized by
the presence of a dense, fibrous network of newly woven bone that surrounds the tumor [110].
Interestingly, although bone scans have generally classified prostate cancer as an osteoblastic
disease, these lesions have usually mixed osteolytic-ostaoblastic phenotype with osteoblastic
appearance dominating over lytic phenotype [111].

This suggests that osteoclastic bone

destruction is necessary to make room for new bone formation [112].
Metastatic bone disease involves extensive remodeling to accommodate rapidly dividing
tumor cells that disseminated to bone. Tumors accomplish this in part by altering their genetic
profile to express proteins that induce bone remodeling [113]. One such group of proteins are
the bone morphogenic protein (BMP) family responsible for new bone and cartilage formation
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but also widely expressed in various tissues regulating proliferation, cell cycle, and calcium
levels among other functions [114]. Studies have also shown that the transcription factor zinc
finger E-box binding homeobox 1 (ZEB1) is expressed in breast cancer cells and promotes the
expression and secretion of inhibitors of BMPs resulting in osteoclastogenesis and bone
destruction to make room for tumor seeding [115]. It is not fully understood what factors in
the bone marrow microenvironment contribute to the gain-of-function mutations acquired by
tumor cells to alter the bone milieu to promote metastatic bone disease.
While evidence suggests that tumor cells can directly contribute to bone remodeling, it
is well-accepted that they predominantly accomplish this by paracrine signaling mechanisms
that accelerate osteoclastogenesis and osteoblastogenesis, although the exact mechanisms are
not well understood [111]. Various tumor-secreted factors expressed by tumor cells have been
implicated in bone remodeling including vascular endothelial growth factor (VEGF) [111]. VEGF
is an important survival and growth factor that initiates endothelial cell proliferation and
survival and regulates vascular formation needed for normal development of long bones,
inflammation and wound healing [116]. VEGF is also expressed and secreted by tumors cells to
promote neovascularization and bone remodeling [117]. Interestingly, VEGF expression by
prostate tumor cells was shown to promote bone mineralization and secretion of osteocalcin, a
marker of late osteoblast differentiation [118]. Studies have reported that blocking signaling
with selective antagonists to VEGF reduces prostate tumor growth in bone and prevents
formation of osteoblastic lesions [118]. Specifically, in vitro studies demonstrated that BMPs
stimulate the ability of prostate cancer cells to enhance osteoblast maturation and function in
part by increasing tumor-derived VEGF [119]. Additional evidence clearly showed that newly
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disseminated prostate cancer cells prefer osteoblast-rich areas of bone [120]. These studies
highlight the deleterious effects of prostate tumor cells colonizing the bone, and underline the
need for understanding the molecular mechanisms behind this process.
As previously mentioned there is an osteolytic component associated with bone seeking
tumors, which makes the metastatic bone disease even more complex. This is evidenced by
both clinical and preclinical studies that demonstrate osteoclast involvement in osteoblastic
bone formation [121]. Primary blood monocytes collected from prostate cancer patients with
osteoblastic lesions spontaneously form more osteoclasts in vitro and serum levels of
osteoclastic markers IL-7 and RANKL are elevated in prostate cancer patients compared to
healthy controls and patients without metastatic disease [121]. Further evidence suggested
that tumor cells that seed in bone early in metastatic disease express dickkopf-1 (DKK-1), a
soluble tumor-derived factor that inhibits WNT-dependent osteoblast function [122].
Additional evidence showed that mice intratibially injected with C4-2B cells that overexpress
DKK-1 produce osteolytic lesions compared to mixed lesions formed by empty vector controls
[123]. This work suggests that DKK-1 may serve as a switch needed to promote initial tumor
colonization before osteoblastogenesis is activated [122], and provide a potential mechanism
for underlying osteolysis in prostate cancer. Other studies have simply attributed the osteolytic
aspect of metastatic bone disease to failed compensatory effort of the bone to repair damage
caused by excessive bone formation [124]. Understanding the molecular mechanisms used by
tumor cells to drive both osteolytic and osteoblastic bone remodeling may reveal novel
therapeutic targets to slow prostate tumor growth in the bone marrow niche.
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1.4 CXCL1 and CXCL2 Signaling Axis is Inflammation and Cancer
1.4.1 CXCL1 and CXCL2 Structure and Functions
CXCL1 (Groα) and CXCL2 (Groβ) are members of the CXC subtype of chemokines,
classified as such by the possession of two conserved cysteine residues separated by an amino
acid (X) [125]. Members of this subtype are characterized by the absence or presence of an ELR
(Glu-Leu-Arg) motif located on the amino terminus immediately before the first cysteine
residue [126]. ELR+ chemokines include CXCL1, 2, 3, 5, 6, 7, and 8 and all serve as potent
angiogenic factors and chemoattractants for neutrophils [125]. Similar to human CXCL1 and
CXCL2, the murine homologs, keratinocyte chemoattractant (KC/CXCL1) and macrophage
inflammatory protein 2 (MIP-2/CXCL2), have 90% homology and bind to the CXC receptor 2
(CXCR2) [127] [128]. Notably, although both chemokines are CXCR2 ligands, CXCL1 seems to
have greater binding affinity [129], which may play a role in modulating inflammatory
responses. CXCL1 and CXCL2 are secreted predominantly by granulocytes, macrophages and
mast cells during bacterial infection to recruit neutrophils and aid in clearance [130]. These
chemokines are also expressed by epithelial cells and evidence suggest they may play a role in
cancer progression [131].
Studies have demonstrated that CXCL1 and CXCL2 are modulated by two signaling
pathways: NFκB and Signal Transducers and Activators of Transcription 1 (STAT1) [132]. Both
NFκB and STAT1 have recognition sites near the promoter regions of CXCL1 and CXCL2 and
regulate their transcription [132]. Others have suggested that JNK mediates CXCL1 expression
as well [133]. More studies are needed to determine the exact mechanism of transcriptional
regulation of CXCL1 and CXCL2 chemokines to better understand how it may be best targeted.
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It is noteworthy that ELR+ chemokines, including CXCL1 and CXCL2, have also been recently
shown to be modified by proteases. In fact, CXCL1 and CXCL2 are cleaved at the amino terminus
by cathepsins K, L, and S, process that markedly enhances their chemotactic functions [134].
Together, transcriptional and post-translation regulation of CXCL1 and CXCL2 may have
important consequences in immunity and disease.
1.4.2 CXCL1 and CXCL2 Signaling Axis in Cancer
CXCL1- and CXCL2-mediated inflammatory responses play roles in tumor cell invasion
and cancer-associated vasculature formation [135].

Fluorescence in situ hybridization (FISH)

analyses of CXCL1 and CXCL2 in cancerous breast tissue revealed that both chemokines are
amplified in 7.5% of primary breast tissue and 19.9% of metastatic tissue compared to
surrounding non-malignant tissue [131]. In vivo studies also demonstrated that tumor volume
and lung metastases are reduced, and caspase 3 cleavage is increased in breast cancer cells
depleted of CXCL1 and CXCL2 [131]. Additional investigations also demonstrated that CXCL1 is
expressed in bladder cancer cells and regulates tumor invasiveness in vitro, and its expression
directly correlates with tumor grade in vivo [136].

Moreover, melanoma cells express and

secrete CXCL1 to support tumor-driven angiogenesis and colony formation and these effects
are inhibited by blocking CXCL1 signaling [137].
Although several studies demonstrated that tumor cells can produce CXCL1 and CXCL2
to drive metastasis and tumor growth, evidence shows that supporting macrophages are a
significant source of these factors. Previous reports revealed that macrophages co-cultured
with breast cancer cells undergo an M1 to M2 phenotype switch and levels of pro-angiogenic
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chemokines, such as CXCL1, are increased [138]. This suggests that M2 macrophages in the
tumor microenvironment promote tumor growth in part by supplying vascular factors that
stimulate vessel formation [138]. Unfortunately, there have only been causal associations
between prostate cancer and increased levels of CXCL1 and CXCL2 [139, 140]. Overwhelming
evidence demonstrates that CXCL1 and CXCL2 are potent drivers in malignancy; however,
studies are needed to determine the effects of CXCL1 and CXCL2 on prostate tumor invasion.
CXCL1 and CXCL2 ligands bind CXCR2 to mediate cellular effects in neutrophils [141] and
cancer cells [142]. CXCR2 is highly expressed on the surface of neutrophils and it binds
chemotactic factors such as CXCL1 to initiate pro-inflammatory responses [143]. Additionally,
CXCR2 overexpression is correlated with tumor growth, invasion, migration and poor patient
prognosis in several cancers [144]. CXCR2 expression is enhanced in kidney [145], prostate
[146], and colon cancers [147]. In vivo studies utilizing TRAMP mice that spontaneously form
prostate tumors, showed that CXCR2 deletion results in smaller tumors and reduced tumor
vasculature [148]. These studies suggest that CXCR2 expression and signaling aid in tumor
growth and progression. More investigations may reveal the potential for novel therapeutics
that target CXCR2 to slow cancer growth.
1.5 Osteopontin Signaling Axis
1.5.1 Osteopontin Expression and Functions
Osteopontin (OPN) also known as secreted phosphoprotein 1 (SPP1) belongs to the
small integrin-binding ligand N-linked glycoprotein (SIBLING) family [149].

OPN is a

multifunctional protein that is involved in several cellular processes that mediate bone
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homeostasis, angiogenesis, inflammation, and cancer [150]. This protein is not very conserved
between species, sharing only 63% homology between human and mouse, and is subject to
extensive translational and post-translational modifications (i.e. glycosylation, phosphorylation,
and sulfation) [151]. There are currently three known isoforms of OPN: OPNa, the full length
isoform, and OPNb and OPNc that lack exons 5 and 4, respectively [149]. Interestingly, these
modifications appear to have opposing effects in vascular tube formation. Studies have shown
that OPNa and OPNb both stimulate new vessel formation and tissue repair while OPNc has
inhibitory effects on tube formation and VEGF expression [150]. Alternative modification of
OPN may prove to be an advantageous target in diseases that rely on osteopontin signaling to
stimulate angiogenic responses in the tumor microenvironment.
OPN is one of the main non-collagenous matrix proteins in bone [151]. It is expressed
by several cell types, including osteoblasts during bone mineralization and induces the
expression of bone forming markers alkaline phosphatase and osteocalcin [152]. Studies
demonstrated that osteoclasts treated with OPN show calcium-dependent activation of nuclear
factor of activated T cells 1 (NFAT1), a factor critical for osteoclastogenesis [153]. Moreover, in
the absence of OPN, NFAT1 signaling is inhibited and prevents successful differentiation of
precursor cells while inducing apoptosis in mature osteoclasts [153]. Similar to osteoclasts,
macrophages depend on osteopontin signaling for survival and function. Specifically, mice
lacking osteopontin display reduced ability to clear debris from tissue following injury [154].
Evidence also suggested that OPN null macrophages have increased expression of mannose
receptor, a marker of M2 phenotype, further suggesting that their pro-inflammatory response
may be impaired [154]. This suggests that osteopontin may be playing a significant role in
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tissue repair and remodeling, particularly in a context of tumor progression.
The many functions of OPN would not be possible without the numerous receptors that
it binds including integrin receptors αVβ3 and α4β1, as well as CD44 and its variant CD44v6, just
to name a few [151]. In vitro studies have shown OPN binds αVβ3 on HUVEC cells to support
cell survival and angiogenesis via increased expression of Akt and ERK1/2 target genes Bcl-xL
and VEGF [155]. CD44-mediated osteopontin signaling is important in insulin resistance and
obesity [156].

Clinical reports showed that levels of OPN and CD44+ macrophages are

enhanced in subcutaneous fat isolated from insulin-resistant patients [157], suggesting adipose
tissue inflammation is partly driven by OPN signaling in macrophages. CD44 and integrin
receptor activation also regulate cell adhesion, motility, and signal transduction via
transcription factors and kinases [150]. The OPN receptor CD44v6, specifically, has been linked
to increased metastatic potential in gastric cancer cells and overall poor prognosis [158]. This
underlines the breadth and diversity behind the OPN signaling in both normal and disease
processes [159], possibly making it a difficult therapeutic target.
1.5.2 Osteopontin Signaling in Cancer
Because OPN has diverse functions in bone remodeling, cell survival, and angiogenesis,
it is no surprise that tumor cells utilize this protein for the very same reasons. In fact, OPN
overexpression was shown to result in the formation of larger colonies in vitro, enhancement of
tumor volume in vivo, and activation of cell survival by regulating HIF-1α and Akt pathways
[160]. Some studies have shown that the splice variant OPNc is the main culprit that mediates
increased Akt signaling, invasion and tumor growth rather than the full length OPNa isoform
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[161]. Clearly, different isoforms have unique functions in tumor progression depend on the
type of cancer. Evidence has also demonstrated that osteopontin may be a predictor of survival
and risk of metastatic disease. Specifically, histological examination of primary and metastatic
bone tissue samples from patients with nasopharyngeal cancer revealed an inverse association
between OPN levels and bone metastasis-free survival [162].
Although tumor-derived OPN has been implicated in tumor progression, its secretion by
tumor-associated cells in the microenvironment has also been suggested as a culprit in this
process. Increased expression of osteopontin in gastric tumors has been mainly attributed to
its secretion by the M2 macrophages and correlated with overall reduced patient prognosis
[163].

This result was in line with in vivo observations demonstrating gastric tumors,

surrounding vasculature, and M2 macrophage infiltration were all reduced in OPN null mice
[163]. Increased OPN expression was also observed in macrophages surrounding vascular and
necrotic regions of glioblastomas [164], suggesting that this protein may be promoting tumor
survival by stimulating neovasculature in hypoxic regions of tumors. As previously mentioned,
some tumors are capable of expressing endogenous OPN to stimulate vascular formation and
immune cell infiltration [165]; however, not all tumors have this capability and must depend on
circulating OPN from the tumor microenvironment. This was demonstrated in a study that
showed OPN knockdown in hepatoma cells decreased tumor cell motility, invasiveness, and
reduced foci formation [166]. Interestingly, when these cells were co-cultured with OPNpositive macrophages, foci formation, tumor invasion and motility were all rescued [166].
These and other studies are a testament that osteopontin signaling in the microenvironment is
a key component of tumor-mediated inflammation and growth.
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There have been intense investigations that have attempted to identify downstream
targets of OPN signalling in tumor cells. Studies have particularly focused on CD44 and its
variant CD44v6 in disease progression [167]. In fact, CD44v6 expression is increased in prostate
cancer cells and supports tumor sphere formation [168]. Moreover, knock down of CD44v6
greatly sensitizes prostate cancer cells to chemotherapy agents such as methotrexate and
docetaxel [168]. In addition, CD44v6 regulates Wnt and Akt activation as well as stem cell
markers Slug, Twist, Snail, and Vimentin [168]. The alternative OPN receptor, αVβ3 has also
been implicated in tumor cell adhesion and migration to bone matrix [169]. Specifically, αVβ3
signaling has been linked to Akt activation via focal adhesion kinase (FAK) phosphorylation to
enhance prostate cancer cell migration and survival [170]. This suggests that OPN-αVβ3 binding
might be an important factor in tumor colonization in bone. All three OPN receptors, CD44,
CD44v6, and αVβ3, seem to have reported roles in tumor cell survival and investigations are
needed to determine other targets of osteopontin that promote tumor progression in bone.
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CHAPTER 2: HYPOTHESIS AND SPECIFIC AIMS
We hypothesized that growth and aggressiveness of metastatic prostate cancer in the
bone is driven by the cooperative effort between bone marrow adipocytes, macrophages,
osteoclasts and metastatic tumor cells in bone. Adipocyte-driven inflammation involving
CXCL1/CXCL2/CXCR2 axis, and macrophage-supplied osteopontin perpetuate the vicious cycle
of bone metastasis by 1) stimulating osteoclastogenesis and bone degradation; 2) promoting
macrophage recruitment and invasiveness; 2) changing the cytokine profiles to those that drive
metastatic events in skeleton; and, consequently 3) increasing tumor cell proliferation,
invasion, and survival in the metastatic niche.

Our project was composed of three specific aims:

Aim 1 was to investigate contributions of marrow adipocyte-supplied CXCL1 and CXCL2 to
tumor-driven osteolysis.
Aim 2 was to determine the role of CXCL1/CXCL2/CXCR2 axis in bone marrow macrophage
phenotype and function in the bone tumor microenvironment.
Aim 3 was to examine the role of macrophage-derived osteopontin in tumor cell survival in
bone.
Overall, these studies were designed to discover novel molecular mechanisms and
pathways behind aggressiveness and survival of metastatic tumors in bone in hopes of
discovering new therapeutic targets for presently incurable metastatic PCa.
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CHAPTER 3: MATERIALS AND METHODS
3.1 Materials
Dulbecco’s modified Eagle’s medium (DMEM), minimum essential medium (MEMα), tartrate
resistant acid phosphatase (TRAcP) staining kit, and other chemicals, unless otherwise stated,
were obtained from Sigma (St. Louis, MO). Fetal bovine serum (FBS) was from Invitrogen
(Carlsbad, CA). Protease inhibitor was from MBL International (Woburn, MA). Rabbit antihuman/mouse cathepsin K antibody was from Abcam (Cambridge, UK).

Rabbit anti-

human/mouse ß-actin antibody was from Novus Biologicals (Littleton, CO). Monoclonal mouse
anti human CXCR2 antibody, recombinant mouse CXCL1 and CXCL2, goat anti-mouse CXCL1 and
CXCL2 neutralizing antibodies, macrophage-colony stimulating factor (M-CSF), receptor
activator of NFκB ligand proteins (RANKL) mouse anti human integrin αVβ3 antibody, goat anti
mouse osteopontin, mouse recombinant osteopontin and Quantikine mouse CXCL1 and CXCL2
ELISA kits were from R&D Systems (Minneapolis, MN). Immunoblotting “Western Lightning ECL
Plus” and “Luminata Forte Western HRP Substrate” detection kits were from Perkin Elmer LLC
(Waltham, MA) and Millipore (Billerica, MA), respectively. RNeasy Mini Kits were from Qiagen
(Valencia, CA). Mouse anti human CD44v6 antibody was from Millipore (Temecula, CA). Mouse
polyclonal to GAPDH and rabbit anti human survivin antibodies were from Novus Biological.
Phosphatase inhibitor, rabbit anti human phosphorylated Akt serine 473 (pAktS473), total Akt,
BiP, Bcl-xL, and CD44, were from Cell Signaling (Danvers, MA).
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3.2 Animals
All experiments involving mice were performed in accordance with the protocol approved by
the institutional Animal Investigational Committee of Wayne State University and NIH
guidelines. In vivo xenograft studies were performed in 8- to 10-week old male mice in the
FVB/N background with homozygous null mutations in the Rag-1 gene (FVB/N/N5, Rag-1−/−).
Mice were bred in-house. Osteopontin KO macrophages were isolated from B6.129S6(Cg)-Spp1
-/- mice and aged-matched C57BL/6J controls purchased from Jackson Laboratories.
3.3 Diets
At 5 weeks of age, mice caged in the groups of 4 were started on either a low-fat (LFD; N = 9)
diet (10 % calories from fat; Research Diets no. D12450Bi) or a high-fat (HFD; N = 11) diet (60 %
calories from fat; Research Diets no. D12492i) as previously described [43].

Mice were

maintained on diets for 8 weeks prior to and 6–8 weeks following the tumor implantation into
bone (total of 16 weeks).
3.4 Cell lines
PC3, an androgen-independent osteolytic cell line derived from a bone metastasis of a highgrade adenocarcinoma [171], and DU145, an androgen-independent osteolytic line derived
from a brain metastasis [172], were purchased from American Type Culture Collection
(Manassas, VA, USA). ARCaP(M), androgen-repressed metastatic prostate cancer cells M
(‘Mesenchymal’ Clone) were purchased from Novicure Biotechnology (Birmingham, AL, USA).
C4-2B human prostate were derived from LNCaP isolated from lumbar spine of athymic mice
[173], were a kind gift from Dr. Leland Chung. L929 cells (source of M-CSF for osteoclast
precursors), were cultured in DMEM containing 10 % FBS until confluent and conditioned media
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was collected, centrifuged, and stored at −80 °C until ready for use. PC3 and DU145 cells were
cultured in DMEM supplemented with 10 % FBS. ARCaP(M) and C4-2B cells were cultured in
RPMI supplemented with 10 % FBS. All cells were maintained in a 37°C humidified incubator
ventilated with 5 % CO2.
3.5 Intratibial injections of tumor cells
Intratibial tumor injections were performed under isoflurane inhalational anesthesia according
to previously published procedures [86]. Briefly, a cell preparation containing 5 × 105 of PC3 or
ARCaP(M) cells in PBS (20 μl, right tibia), or PBS alone (control, 20 μl, left tibia) was injected into
the bone marrow. 6 or 8 weeks post-injection (for PC3 and ARCaP(M) cells, respectively) mice
were euthanized, and control and tumor-bearing tibiae were removed and imaged ex vivo. Xray images were obtained using a Carestream XVivo Multimodal Animal Imager. Half of the
intratibial tumor samples from each group were then fixed in Z-fix, bone tumors were
decalcified, and all samples were embedded in paraffin. The 5 μm longitudinal sections from
tibiae were deparaffinized, and stained with tartrate resistant acid phosphatase (Sigma Aldrich)
according to the manufacturer’s instructions. Digital images were captured under ×5 and ×10
magnification using a Zeiss Scope A.1 conventional light microscope with CCD camera.
Remaining tissues were snap-frozen in liquid nitrogen, powderized using a tissue pulverizer and
RNA was isolated using Trizol and RNeasy Mini Kit.
3.6 Bone marrow adipocyte-conditioned medium
Primary mouse bone marrow stromal cells (mBMSC) were isolated from femurs and tibiae of 6to 8- week old FVB/N mice and induced to become bone marrow adipocytes as previously
described [43]. Briefly, mBMSC cells were plated in 3D collagen I gels, grown to confluency for
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48–72 h and treated with adipogenic cocktail (30 % StemXVivo Adipogenic Supplement, 1 μM
insulin, 2 μM Rosiglitazone; DMEM and 10 % FBS) for 8–10 days. Differentiated bone marrow
adipocyte cultures were cultured in serum-free DMEM for 12–16 h and medium was collected,
centrifuged, and stored at −80 °C. Prior to use, serum-free medium collected from adipocyte
cultures was diluted 1:1 with MEMα appropriate for osteoclast treatment and designated
‘Adipo CM’. Cells were maintained in a 37 °C humidified incubator ventilated with 5 % CO2.
3.7 Isolation of BMMs
Bone marrow macrophages (BMMs) were differentiated from primary murine bone marrow
cells. Bone marrow was flushed from femurs and tibiae of 10 to 12-week-old FVB/N male mice
with BMM growth medium (MEMα containing 20 % FBS and 30 % L929 conditioned medium as
the source of M-CSF [86]). For comparison of BMMs in OPN WT versus KO mice, B6.129S6(Cg)Spp1 -/- mice aged-matched C57BL/6J were used. The cell suspension was plated on petri
dishes and incubated for 4–5 days to obtain differentiated bone marrow macrophages (BMMs).
3.8 Adipocyte and BMM co-culture with PC3 tumor cells
For indirect adipocyte-tumor cell co-cultures, mBMSC cells were seeded in collagen I-coated 6well plates, differentiated into adipocytes, and 200,000 tumor cells were seeded on top of a
Transwell filter (0.2 µm pore size) to allow sharing of soluble factors between the two cell
types. Cells were cultured as described for 48 h and serum-starved for additional 12–16 h prior
to sample collection for analyses. For ELISA analyses, media were concentrated through 3 K
Millipore centrifugal filters, and all samples were stored at −80 °C for future use.
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3.9 BMM co-culture with PC3 and ARCaP(M) tumor cells
For indirect BMM-tumor cell co-cultures, primary BMMs were seeded in 6-well plates, at a
density of 300,000 cells per well and 200,000 tumor cells were seeded on top of a Transwell
filter and cultured in the absence or presence of Adipo CM. To determine if CD44v6 and αVβ3
receptors promoted survival and ER stress in co-culture, blocking antibodies to CD44v6 and
αVβ3 (0.8μg/mL) were also added. To determine changes in tumor survival in BMM-PCa coculture, PC3 cells we plated at a density of 300,000 cells on 6-well plates and cultured with 5
and 10 nM of docetaxel for 48 hours. Macrophages were seeded at a density of 300,000 cells
per well on Transwell filters and cells were allowed to recover. For RNA isolation, cells were
washed with PBS cells and collected into RLT buffer and RNA purified according to the RNeasy
Mini Kit instructions. For lysate and media, cells were cultured as described for 48 h and serumstarved for additional 12–16 h prior to sample collection of lysates and media for analyses. Cells
were washed three times with PBS, collected in SME lysis buffer (250 mM sucrose, 25 mM 2-(Nmorpholino) ethanesulfonic acid (MES), 1 mM EDTA, 0.1 % Triton-X 100 pH 6.5) containing
protease and phosphatase inhibitors. All samples were then stored at −80 °C for future use. To
induce hypoxia, co-cultures were treated with 100uM cobalt chloride for 48 hours.
3.10 Osteoclast formation for tartrate resistant acid phosphatase staining
BMMs were seeded at a density of 250,000 cells per well in a 24-well dish on glass coverslips in
BMM growth medium as described above and allowed to attach overnight. For
osteoclastogenesis assays, cells were cultured with 1:1 ratio of MEMα and DMEM or Adipo CM
containing 10 % FBS, 20 ng/mL M-CSF and 10 ng/mL RANKL. Assays were performed in the
absence or presence of recombinant proteins to CXCL1 (0.5 μg/mL) and CXCL2 (0.25 μg/mL),
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neutralizing CXCL1/CXCL2 antibodies (3 μg/mL), CXCR2 neutralizing antibodies (5 μg/mL) or
CXCR2 antagonist SB225002 (2.5 μM; from Cayman Chemical, Ann Arbor, MI). Every 48 h, half
of the medium was removed and replenished with fresh medium supplemented with M-CSF,
RANKL and appropriate treatment reagents.

Data were collected from at least three

independent experiments, each performed in duplicate. Osteoclasts were formed within 4–6
days and TRAcP staining was performed according to manufacturer’s instructions.
3.11 Quantification of TRAcP-positive cells
TRAcP-positive cells that contained three or more nuclei were considered osteoclasts and
counted. Six representative images per coverslip were captured using a Zeiss Scope A.1
conventional light microscope at 5x magnification to evaluate the number and surface area of
osteoclasts per field. For each experimental condition, the total number and cell surface area
of osteoclasts were manually counted using ImageJ software.
3.12 RNA and lysate isolation of osteoclasts
BMMs were seeded at a density of 500,000 cells per well in a 12-well dish for 24 h as described
above. BMMs were then treated with RANKL and M-CSF in the presence or absence of Adipo
CM. When indicated, cells were treated with recombinant CXCL1 and CXCL2 proteins,
CXCL1/CXCL2 neutralizing antibodies, CXCR2 blocking antibody, or CXCR2 antagonist SB225002
as described above. Following formation of mature osteoclasts, cells were washed three times
with PBS, collected in SME lysis buffer (250 mM sucrose, 25 mM 2-(N-morpholino)
ethanesulfonic acid (MES), 1 mM EDTA, 0.1 % Triton-X 100 pH 6.5) and stored at −80 °C for
future use. For RNA isolation, cells were washed with PBS cells and collected into RLT buffer
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and RNA purified according to the RNeasy Mini Kit instructions.
3.13 Taqman RT-PCR analyses
The cDNA from cells and in vivo samples was prepared from 1–2 μg of total RNA using HighCapacity cDNA Reverse Transcription kit (Applied Biosystems) as previously described [86].
Analyses of genes associated with bone remodeling and inflammation were performed using
mouse-specific TaqMan® Individual Gene Expression assays for cathepsin K (Mm00484039),
matrix metalloproteinase-9 (Mm00442991), calcineurin (Ms00432282), CXCL1 (Mm01354329),
CXCL2 (Mm00436450), and DC-STAMP (Mm04209236). Murine genes were normalized to
HPRT1 (Mm00446968) and 18S (Mm03928990). Genes associated with ER stress, hypoxia, and
cell survival in PCa cells were analysing using probes for BCL2 (Hs00608023), BAX (Hs00180269),
and CA9 (Hs00154208), and VEGF (Hs00900055) and were normalized to HPRT1 (Hs99999909).
Analysis of mRNA expression of XBP-1 in tumor cells was performed by reverse transcription
using Taqman Master Mix (Qiagen). PCR for XBP1 expressions was performed using forward
and

reverse

primers

XBP1a

(5’CCTGGTTGCTGAAGAGGAGG

3’)

and

XBP1b

(5’

CCATGGGGAGATGTTCTGGAG 3’) and normalized to β actin a (5’ GGATGCAGAAGGAGATCACTG
3’) and β actin b (5’ CGATCCACACGGAGTACTTC 3’). Human osteopontin (Hs Hs00959010) was
also assessed and normalized to human 18S (Hs03003631). M1 and M2 markers assessed were
arginase-1

(Ms00475988),

IL-10

(Ms00439614),

NOS2

(Ms004404851),

and

CD163

(Ms00474091). Human specific gene expression assays of CXCR2 were performed using Taqman
probes Hs01891184 (recognizes amplicon length 64bp) and Hs00174304 (recognizes amplicon
length of 95bp). Primary human neutrophil cDNA was kindly provided by Dr. Kingsley Osuala,
Wayne State University to serve as a positive control for CXCR2 expression. Assays were done
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on three biological replicates using TaqMan® Fast Universal PCR Master Mix and 25 ng of
cDNA/well for RNA isolated from cells and 50 ng cDNA/well for in vivo samples. All reactions
were run on an Applied Biosystems StepOnePlus™ system. DataAssist™ Software (Applied
Biosystems) was used for all analyses.
3.14 Immunoblot and ELISA analyses
Lysates were equally loaded based on DNA concentrations as previously described [85, 86].
Proteins were electrophoresed on 12 % SDS-PAGE gels, transferred to PVDF membranes and
immunoblotted for cathepsin K (1:500) and β-actin (1:5000), pAktS473, total AKT, Bcl-xL, BiP,
survivin, CD44, CD44v6, αVβ3, and OPN (1:1000). Secondary antibodies labeled with
horseradish peroxidase were used at 1:10,000. Quantification and analyses of bands were
performed using a Luminescent Image Analyzer LAS-1000 Plus from Fujifilm (Stamford, CT) and
expressed as arbitrary units (AU) per square millimeter. For ELISA assays, media from each
condition were diluted based on DNA concentrations in cell lysates and were run in duplicate
according to manufacturer’s instructions (R&D Systems). Optical density of each well was
determined at 450 nm with correction wavelength set to 540 using TECAN-Infinite M200 PRO
plate reader (Männedorf, Switzerland). The data were analyzed based on the standard curve
values using a four parameter logistic (4-PL) curve-fit.
3.15 Cathepsin K activity assay
Enzymatic activity of cathepsin K was measured in cell lysates utilizing the fluorescent substrate
Z-Glycine-Proline-Arginine-7-amido-4-methylcoumarin-HCl (Z-Gly-Pro-Arg-AMC) from Bachem
Chemical (100 μM; Torrance, CA). The reaction was performed in the presence of the selective
inhibitor to cathepsin B, CA074 (1 μM) to eliminate the activity due to cathepsin B-mediated
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cleavage of Z-Gly-Pro-Arg-AMC [85]. The progress of the reaction was monitored every minute
for a period of 30 min on a Tecan SpectraFluor Plus plate reader. Results of activity assays are
expressed as maximum fluorescence units formed per minute. Equal amounts of cell lysate
were used based on DNA concentrations in cell lysates.
3.16 MTT assay
BMMs were seeded at a density of 20,000 cells per well in a 96-well in MEMα medium with
15% L929 conditioned medium and 10 % FBS. After 24 h, cells were treated with DMSO
(control) or increasing concentrations of SB225002 or CXCR2 neutralizing antibody. Cells were
retreated after 48 h and Vybrant® MTT Cell Proliferation Assay kit (Life Technologies) was
performed

after

4

days.

Conversion

of

MTT

(3-(4,5-dimethylthiazol-2-yl)-2,5-

diphenyltetrazolium bromide) to formazan by viable tumor cells was measured at 540 nm
according to manufacturer’s instructions using Infinite® F200 Pro plate reader.
3.17 Immunofluorescence Analysis
Cytoplasmic and surface expression of CD44v6 were examined by immunofluorescence staining
using goat anti-human CD44v6 (1:50) primary antibody and Alexa 488 secondary antibodies.
Fluorescent images were captured with a Zeiss LSM510 META NLO confocal microscope using
40x oil immersion lens. Controls were run in the absence of primary antibodies.
3.18 Flow cytometry analysis of CD44v6 and αVβ3
ARCaP(M) tumor cells were seeded at a density of 1.3x106 cells per well in 100mm dishes and
allowed to settle overnight. Half of the growth medium was removed and replaced with DMEM
containing 10% FBS (Control) and 200 ng/mL OPN for 48 hours. Cells were trypsinized and
washed 2x with PBS. Cells from control and OPN treated conditions were counted and at least
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1x106 cells were used for antibody labelling. Cells were labelled with CD44v6 (1:100), CD44
(1:50) and αVβ3 (1:20) in 100ul PBS and incubated at RT for 1 hour and washed 2x with PBS.
Cells were resuspended in 100ul PBS and Alexa Fluor 488 secondary anti mouse and anti-rabbit
secondary antibodies and incubated for 30 minutes protected from the light. Cells were washed
2x with PBS and pellet was resuspended in 1ml PBS and kept on ice. Analyses of CD44v6 and
αVβ3 were performed using BD LSR II Analyzer.
3.19 Invasion Assays
To determine the effects of BMM-secreted OPN in tumor invasion, BMMs were seeded at a
density of .1 x 106 cells per well in a 24-well plate and allowed to settle overnight. Tumor cells
were serum starved overnight and seeded on top of the BD invasion filter (8 μm pore size)
coated with 3-D Culture Matrix™ reduced growth factor basement membrane extract
(Trevigen, 1mg/ml). Tumor cells were then seeded at the density of 5 × 104 cells/filter in serumfree medium in the presence or absence of blocking antibodies to αVβ3 (0.8μg/mL), CD44v6
(0.8μg/mL), or recombinant OPN protein (500ng/mL) and allowed to invade to BMM media
containing 10% FBS and MEMα (control) or BMMs to serve as a chemoattractant. Cells were
allowed to invade for 48 hours and filters were stained with Kwik Diff Staining kit (Thermo
Scientific) according to manufacturer’s instructions. Five representative images per coverslip
were captured using an Olympus BX43 conventional light microscope at 10X magnification to
visualize invading cells and counted using ImageJ software. Data were collected from at least
three independent experiments performed in duplicate.
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3.20 OPN mRNA Expression in Primary vs Metastatic Sites Using OncomineTM Database
Gene expression of osteopontin in primary prostate compared to metastatic prostate cancer
was

performed

using

publicly

available

microarray

datasets

in

Oncomine TM

(www.oncomine.org). Data were graphed using Box and Whisker plots and fold increase in
primary and metastatic prostate tissue were compared to normal prostate tissue. Changes in
gene expression were represented as log2 median-centered intensity.
Statistical analyses
All data analyses were performed using GraphPad Software version 6.05. Data were presented
as mean +/− SEM and statistically analyzed using Student’s t test. For three or more groups,
one-way analysis of variance was used.
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CHAPTER 4: MARROW ADIPOCYTE-DERIVED CXCL1 AND CXCL2 CONTRIBUTE TO OSTEOLYSIS
IN METASTATIC PROSTATE CANCER

4.1 Introduction
Bone has critical functions in haematopoiesis, metabolism, inflammation, and structural
support [42, 174]. Multiple proteins and cell types in the bone marrow maintain and preserve
normal bone homeostasis [42]; however, this balance is often disrupted by diseases involving
chronic inflammation and changes in bone remodeling induced by rheumatoid arthritis [175],
diabetes, osteoporosis [35, 176, 177], and metastatic cancers of the breast and prostate [178].
One important part of the bone marrow is the adipocyte, a cell type that not only stores and
secretes lipids and fatty acids to promote metabolic functions in the bone, but also secretes
adipokines, cytokines, and other inflammatory factors [176, 177, 179]. It is already known that
adiposity of the bone marrow increases greatly with age, obesity, and metabolic disorders [42,
176, 177]. There is also growing evidence that the number of adipocytes in the bone is
inversely correlated with bone mineral density [34, 42, 176, 180-182].
Bone marrow fat is particularly localized to trabecular areas of the bone, sites of active
remodeling, suggesting that it may have some involvement in bone degradation [176].
Different factors have been reported to be associated with increased bone marrow adiposity
and altered bone health. They include a shift in mesenchymal cells from osteoblasts to
adipocytes resulting in reduced bone mass [179, 180, 183], fatty acid-driven promotion of
osteoclastogenesis and prolonged survival, enhanced PPARγ expression [184, 185], and
increased levels of osteoclastic factors: macrophages colony-stimulating factors (M-CSF) and
receptor activator of nuclear factor κB ligand (RANKL) [176, 180]. It is less well known if
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adipocytes supply other factors that promote normal M-CSF/RANKL-driven osteoclastogenesis.
Studies of bone marrow adiposity in mouse models fed a high fat diet (HFD) have linked
decreases in trabecular bone volume and bone marrow density with enhanced expression of
the bone-degrading protease cathepsin K, pro-inflammatory cytokines, IL-6 and tumor necrosis
factor α (TNF-α) and decreased expression of IL-10, a negative regulator of osteoclast
maturation [181, 182, 186-188]. We have recently shown that COX-2 and CCL-2, two hostderived inflammatory factors, are increased in bones of mice on HFD [43]. We also reported
that increased marrow adiposity has stimulating effects on growth of skeletal prostate tumors
[43], similar to previous studies indicating that fatty marrow is a storage depot for protumorigenic factors important for tumor colonization [189, 190].
Two such factors are members of the CXC chemokine family, CXCL1 and CXCL2, potent
chemotactic proteins that promote inflammation and support tumor growth [191]. CXCL1 and
CXCL2 bind to CXCR2 (IL-8RB), a Gαi protein coupled receptor expressed on macrophages,
epithelial cells, and neutrophils [130, 131, 141, 192] and their normal function is to attract
neutrophils to sites of injury [191]. Although the role of CXCR2 in the inflammatory response is
well characterized, the functions of CXCL1 and CXCL2 signaling in osteoclast precursor cells and
its function in bone remodeling is not well understood [193].

Only recently a possible

involvement of CXCL1 and CXCL2 in migration and differentiation of osteoclast precursor cells
was suggested by some studies [194, 195]. CXCR2 and its ligands have been linked to the
progression of several malignancies including melanoma, non-small cell lung cancer, and
pancreatic cancer (reviewed in [196]); however, to date there have been no studies that have
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determined the role of CXCR2 in adipocyte-associated deregulation of bone remodeling and the
deleterious consequences on tumor progression in bone.
The objective of the present study was to investigate the role of CXCL1 and CXCL2 and
their receptor CXCR2 in adipocyte-induced osteoclast differentiation and in prostate tumordriven bone degradation. Utilizing diet-induced obesity model, a well-documented approach to
induce bone marrow adiposity [42, 177, 181, 188], we demonstrate a positive association
between bone marrow adiposity, augmented levels of CXCL1 and CXCL2, and bone degradation
by ARCaP(M) and PC3 prostate tumor cells. By in vitro osteoclastogenesis assays, we also show
that media conditioned by bone marrow adipocytes accelerates osteoclast maturation and
increases gene expression of proteolytic factors important for osteoclast formation and
function. We also show that bone marrow adipocytes are a significant source of CXCL1 and
CXCL2, chemokines levels of which are potentiated by adipocyte-tumor cell interactions. In
addition, we demonstrate that neutralization of the CXCR2 receptor or CXCL1/CXCL2 ligands
effectively abrogates osteoclast formation. Together, our results demonstrate a mechanism of
the contribution of bone marrow adiposity to tumor-stimulated osteolysis.
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4.2 Results
4.2.1 Bone remodeling is increased in tibiae of mice with increased marrow adiposity
Bone marrow adiposity has been linked to reduced bone density, increased presence of
osteoclasts, fewer osteoblasts, and accelerated growth of prostate cancer in bone [197, 198].
We previously demonstrated that mice fed HFD have more adipocytes in marrow compared to
LFD control mice [43]. We also showed that the increased adiposity promotes growth of PC3
prostate tumors in bone [43]. Based on these findings we investigated the effects of marrow
adiposity in intratibially implanted ARCaP(M) cells. These cells have a mixed osteoblastic and
osteolytic phenotype in vivo, and better reflect the metastatic phenotype in humans [199, 200].
Under LFD conditions, ARCaP(M) tumors remained contained within the bone matrix with X-ray
and histological evidence of both bone destruction and new bone acquisition (Figure 4.1 A–E),
whereas HFD tumors exhibited extensive destruction of the bone (Figure 4.1 F–J).
We validated these results by measuring the area of each tibia that is not occupied by
tumor and showed significant reduction in intact bone in tumor-bearing mice fed HFD as
compared to LFD mice (Figure 4.2). These data confirm our previous report of adipositystimulated bone destruction in mice bearing PC3 tibial tumors [43]. To better visualize the
effects of bone marrow adiposity-driven effects of tumor growth on osteolysis and the location
of osteoclasts in these models, we performed TRAcP staining of tibial cross-sections of PC3- and
ARCaP(M)-bearing mice. Our results verified our histological and X-ray analysis showing LFD
tumors are confined to the bone and surrounded by TRAcP-positive cells at the bone-tumor
[43] interface (Figure 4.1 D, E, Figure 4.3 C, E). In comparison, HFD tumors resulted in
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substantial bone destruction and large osteoclastic clusters were observed both around bone
remnants as well as in the tumor (Figure 4.1 I, J, Figure 4.3 D, F). Together, these data suggest
that bone marrow adiposity accelerates tumor-derived osteolysis in vivo.
4.2.2 Adipocyte-derived factors enhance osteoclastogenesis and proteolytic activity of
osteoclast-derived cathepsin K in vitro
To determine the effects of adipocyte-derived factors in osteoclastogenesis, we
differentiated osteoclasts in vitro in the absence or presence of conditioned medium from bone
marrow adipocytes (Adipo CM). Assays were performed in the presence of M-CSF and RANKL,
both required for the induction of osteoclastogenesis [201]. As shown in Figure 4.4, treatment
with Adipo CM resulted in increased osteoclast maturation compared to cultures treated with
RANKL and MCSF alone (Figure 4.4 A, B). Upon closer examination, we observed there were
significantly larger TRAcP-positive cells formed in addition to an increase in the total number of
osteoclasts differentiated in the presence of Adipo CM compared to control (Figure 4.4 C, and
D). Osteoclast formation was due to enhanced BMM fusion, as indicated by the formation of
multi-nucleated cells and increased expression of the osteoclast fusion marker DC-STAMP [202]
by osteoclasts differentiated in the presence of Adipo CM (Figure 4.5 A, B).

Bone marrow

adiposity-driven osteoclastogenesis was further demonstrated by significant increases in genes
correlated with osteoclastogenesis and bone remodeling including calcineurin, cathepsin K, and
matrix metalloproteinase-9 (MMP-9) [203-205] (Figure 4.6 A).
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We further investigated changes in cathepsin K protein expression and activity in Adipo
CM-treated osteoclasts since it is one of main proteases expressed by osteoclasts, and known
to degrade collagen, a matrix protein that makes up 90% of the bone matrix [206]. Consistent
with our RT-PCR analyses, total protein expression of the full-length and mature active forms
cathepsin K were increased in lysates of Adipo CM-treated osteoclasts (Figure 4.6 B). To
determine if Adipo CM-treated osteoclasts expressed active cathepsin K, we also performed
proteolysis assays and measured the amount of cleavage of cathepsin K substrate, Z-Gly-ProArg-AMC. Indeed, osteoclasts differentiated in the presence of Adipo CM had 5 times more
activity than control cells (Figure 4.6 C). These results suggest that adipocyte-derived factors
accelerate osteoclastogenesis beyond the RANKL- and M-CSF-induced stimulation.
4.2.3 Marrow adiposity is associated with increased levels of CXCL1 and CXCL2
Previously, we showed that adiposity promotes increased production of COX2 and CCL2,
inflammatory factors implicated in bone metabolism, osteoclast differentiation, and metastatic
tumor growth in bone [42]. This suggested bone marrow adiposity induces changes in the
microenvironment to promote tumor progression in bone, and we investigated if other
adipocyte-derived factors may also be involved in this process. Of the various factors we found
to be increased in our ARCaP(M) and PC3 HFD tumor models, two that stood out were CXCL1
and CXCL2 (Figure 4.7 A).

Notably, CXCL1 and CXCL2 have been implicated in several

malignancies such as endometrial and ovarian cancer and have been reported to regulate
tumor invasiveness [207], and, most recently, to stimulate migration of osteoclasts pre-cursor
cells and promote differentiation [194, 195]. We performed RT-PCR analyses of CXCL1 and
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CXCL2 in bone marrow adipocytes cultured in Transwell with PC3 and ARCaP(M) cells, and there
was in fact increased expression of these pro-inflammatory chemokines in response to PCaderived factors (Figure 4.7 B). We also performed ELISA analysis of conditioned media from the
Transwell co-cultures to verify that secretion of CXCL1 and CXCL2 corresponded with gene
expression (Figure 4.7 C). Indeed, both factors were secreted by adipocytes (399.2 pg/mL for
CXCL1 and 3.111pg/mL for CXCL2) and secretion was further increased during interaction with
PCa tumor cells (7.5- fold increase for CXCL1 and 54-fold increase for CXCL2). These data show
that bone marrow adipocytes contribute to tumor-induced inflammation in bone.
4.2.4 CXCL1 and CXCL2 chemokines stimulate osteoclast differentiation in vitro
To investigate the role of CXCL1 and CXCL2 in osteoclastogenesis, we differentiated
osteoclast precursor cells in the absence or presence of recombinant proteins to each of the
chemokines. TRAcP staining showed that CXCL1 and CXCL2 markedly increased osteoclast
differentiation compared to control conditions (Figure 4.8 A-C). Interestingly, although the
total number of osteoclasts did not change significantly between conditions, both chemokines
promoted the formation of substantially larger osteoclasts compared to those differentiated in
the absence of CXCL1 and CXCL2 (Figure 4.8 D-E). Likewise, increased mRNA levels of cathepsin
K paralleled the clear presence of larger osteoclasts as established by TRacP staining (Figure
4.9). Conversely, we determined whether osteoclastogenesis can be inhibited by neutralizing
antibodies to CXCL1 and CXCL2 (Figure 4.10 A). We observed a considerable reduction in both
the total number of osteoclasts formed (Figure 4.10 B) and size of osteoclasts formed
compared to Adipo CM alone (Figure 4.10 C). These results demonstrate that CXCL1 and CXCL2
are in part involved in adipocyte-driven osteolysis.
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4.2.5 Osteoclastogenesis is partially regulated by the CXCR2 signaling axis
As previously discussed, CXCL1 and CXCL2 bind to the G-protein coupled receptor CXCR2
[130]. Importantly, CXCR2 is highly expressed in osteoclast precursor cells [208] and studies
have shown that binding of another CXCR2 ligand IL-8 in human monocytes promotes
osteoclastogenesis [193]. To date, however, the role of CXCL1 and CXCL2 signaling through
CXCR2 in promoting osteoclast formation has not been well-characterized.

Since we

established a role of CXCL1 and CXCL2 in osteoclastogenesis, we determined whether blocking
CXCR2 and subsequent downstream signaling of the ligands would suppress this process. We
treated osteoclast precursors with Adipo CM in the presence or absence of blocking antibodies
to CXCR2 or an antagonist to CXCR2, SB225002. We determined effective doses of CXCR2
antibody (5μg/mL) and the CXCR2 antagonist (2.5μM) by TRAcP and MTT assays and showed
that both the blocking antibodies and antagonist are not toxic to osteoclast precursors (data
not shown).
Similar to the effects of blocking CXCL1 and CXCL2, blocking the CXCR2 receptor with
antibodies or an antagonist substantially abrogated osteoclast formation (Figure 4.11 A).
Likewise, the total number and size of the osteoclasts formed was reduced compared to Adipo
CM treatment alone (Figure 4.11 A-C). To further establish the effects of the CXCR2 signaling
axis in this process, we assessed gene and protein expression of osteoclast markers calcineurin,
cathepsin K and MMP-9 in osteoclasts treated with Adipo CM in the presence or absence of
CXCR2 antibodies. mRNA levels of all three genes were reduced in the presence of blocking
antibodies (Figure 4.12 A). Additionally, both protein expression and activity of cathepsin K
were reduced with antibody treatment (Figure 4.11 B-C). These results confirm the role of
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CXCR2 signaling in bone marrow adipocyte-induced osteoclastogenesis.
4.3 Discussion
Accelerated bone destruction is a debilitating condition associated with metastatic
tumor progression in bone [42, 198, 209, 210]. Almost 80% of men with metastatic prostate
cancer present with bone lesions [211], and though most lesions appear osteoblastic, strong
evidence supports these lesions are formed by the cooperative dysregulation of osteoclastic
and osteoblastic activity [121, 212-214]. Notably, increased bone marrow adiposity and altered
adipocyte metabolism are features associated with aging and accelerated osteolysis [34, 42,
179-182]. Moreover, bone marrow adipocytes are usually concentrated in areas of active bone
remodeling, such as the trabecular bone [176], and areas rich in red marrow within the axial
skeleton [189, 215]. Interestingly, these areas of bone are also preferred sites of metastatic
tumor cell seeding and growth [31, 216]. We previously demonstrated that HFD-induced bone
marrow adiposity accelerates growth of PCa prostate tumors in bone [43]. In line with previous
findings reported by others [189, 215, 217, 218], we demonstrated lipid transfer between bone
marrow adipocytes and prostate tumor cells has effects on stimulating growth and invasion.
These interactions result in significantly larger skeletal tumors as well as extensive bone
destruction [43].
Emanating from our previous findings, the present study focused on the role of bone
marrow adiposity on tumor-driven osteolysis of the bone. We showed that HFD-fed mice
exhibit more pronounced bone degradation when intratibially injected with either PC3 or
ARCaP(M) tumors (Figure 4.1- 4.3). We also demonstrated that gene expression of host-derived
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CXCL1 and CXCL2 is significantly higher in tumor-bearing mice on HFD compared to LFD mice
and both chemokines are highly secreted by bone marrow adipocytes in vitro (Figure 4.7).
Moreover, Adipo CM accelerated osteoclast differentiation, a process that can be simulated by
treating osteoclast precursors with recombinant CXCL1 and CXCL2 ligands (Figure 4.8).
Conversely, the inhibition of adipocyte-driven osteoclast differentiation by the neutralizing
antibodies or agents that block the CXCR2 receptor strengthened the importance of CXCR2
signaling in this process (Figure 4.10).
The role of the CXCR2 and its ligands CXCL1 and CXCL2 is osteoclastogenesis has only
recently been investigated. Limited reports suggested these chemokines play a role in migration
and/or differentiation of osteoclasts [194, 195] and promoting bone loss in periodontal disease
[195], rheumatoid arthritis [208], and oral squamous cell carcinoma[219]. Much less is known
about the activities of adipocyte-derived CXCL1 and CXCL2 in this process. CXCL1 has been
shown to be highly expressed by 3T3-L1 adipocytes co-cultured with macrophages [220], and
has also been implicated in inducing inflammation in white adipocytes [221]. Other studies
demonstrated that obese individuals have increased levels of CXCL2 in pre-adipocytes, mature
adipocytes, and peripheral blood mononuclear cells [222, 223]. Together, these studies suggest
a possible link between CXCL1 and CXCL2 in adipocyte-derived inflammation and its relevance
to changes in bone tumor milieu. Our lab has previously reported evidence of BMM-driven
inflammation in prostate tumors grown in bone, proposing cooperative relationship between
tumor cells, bone marrow adipocytes, and osteolysis in bone [86]. We have also shown that
augmented levels of bone marrow macrophages result in overexpression of host COX-2 and
MCP-1 in skeletal prostate tumors [42]. This present work highlights CXCL1 and CXCL2 as two

58

additional host-derived pro-inflammatory factors that are augmented in metastatic bone
tumors with increased bone marrow adiposity. This inflammatory response in the tumor bone
microenvironment may be due to enhanced presence of bone marrow fat as our data show
that HFD mice have higher expression of CXCL1 and CXCL2 compared to LFD mice (data not
shown).
In addition to bone marrow adipocytes, there are other inflammatory cells in the bone
that may be sources of CXCL1 and CXCL2 including tumor cells, endothelial cells, and
macrophages [130, 191, 224], which may possibly explain why CXCL1 and CXCL2 levels are
upregulated in HFD mice (Figure 4.7 A). Several groups have shown that macrophage- and
endothelia-secreted CXCL1 and CXCL2 function as mediators in neutrophil recruitment to sites
of tumor growth [130, 191, 216]. Importantly, evidence suggests that tumor cell-derived CXCL1
and CXCL2 may be important in chemoresistance and metastasis [131]. Various sources of these
chemokines secreted into the bone microenvironment may have direct effects on bone marrow
adipocytes; however, it is unknown if this promotes osteolysis and tumor growth in bone.
Regardless of the multiple sources of CXCL1 and CXCL2 in the bone, our results clearly uncover
specific roles for these adipocyte-supplied chemokines in osteoclast differentiation. This was
clearly demonstrated in this study when neutralizing antibodies to CXCL1 and CXCL2 abrogated
adipocyte-induced osteoclastogenesis (Figure 4.10). These effects were mirrored by blocking
ligand binding to the CXCR2 receptor (Figure 4.11), highlighting the important function of
CXCR2 signaling in osteoclast maturation. It is noteworthy that additional ligands of CXCR2
could possibly contribute to adipocyte-driven osteoclastogenesis including CXCL8 (IL-8) and
CXCL5. Both chemokines have been reported as stimulators of osteoclast differentiation and
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function [193, 225, 226] and are present in adipose tissue; however, CXCL5 and CXCL8
expression is principally associated with the stromal portion of adipose tissue [227-229]. This
suggests that bone marrow adipocyte-derived CXCL1 and CXCL2 chemokines, in part, drive
CXCR2 signaling in osteoclasts. However, further studies are necessary to fully understand
function and expression of CXCR2 ligands in bone marrow adipocytes, which has been shown to
have different features than white adipose tissue [42, 230].
Although diet-induced adiposity is a well-documented and acceptable method to induce
bone marrow adiposity [43, 177, 181, 187], we cannot discount possible consequences of the
diet on bone degradation and tumor growth. Further studies using genetic models of obesity as
well as age-induced models of bone marrow adiposity will provide greater insight into the
function of fat-derived CXCL1 and CXCL2 in tumor-driven bone degradation. Increased bone
marrow adiposity promotes changes in the bone marrow microenvironment that prove
deleterious to bone health with increased age, obesity, and metabolic disorders. Although, the
work presented herein did not investigate the effects of diet on the bone milieu, our results do
suggest that adipocytes have stimulatory effects on tumor-driven osteolysis through secretion
of CXCL1 and CXCL2 and activation of CXCR2 on osteoclast precursors. To our knowledge, this is
the first study that directly attributes adipocyte-supplied CXCL1 and CXCL2 with accelerated
osteolysis to aid in prostate tumor progression in bone.
This work contributes to the understudied mechanisms associated with the involvement
of marrow adiposity in the maintenance of bone health and regulating tumor behavior in bone.
Unfortunately, therapies for metastatic bone disease such as bisphosphonate zoledronic acid
and the monoclonal antibody denosumab remain palliative [213, 214]. Moreover, no studies
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have assessed the possible effects of CXCR2 targeted-therapy as an option in bone disease
because of its important roles in normal immunity and other biological functions. The evidence
provided in this study and previous reports on the roles of macrophages and adipocytes in
tumor progression in bone [42, 43, 86], demonstrate that multi-targeted and combinational
therapies may be necessary to effectively reduce the incidence and growth of tumors in
metastatic bone disease.

Particularly, therapies that target adipocyte, osteoclast, and

macrophage pathways may be advantageous in improving quality of life, prolonging survival,
reducing bone pain, and eradicating the disease.

61

CHAPTER 5: Bone Marrow Adiposity Promotes Secretion of Macrophage-Supplied CXCL1 and
CXCL2 to Support Tumor Invasion
5.1 Introduction
Inflammation plays a significant role in various diseases including metabolic syndrome,
obesity, arthritis, and cancer [231, 232]. Studies have shown that prostate cancer progression
and aggressiveness are positively associated with obesity and inflammation and result in
increased mortality [233].

Increased subcutaneous adiposity promotes infiltration of

macrophages, which can take up as much as 40% of adipose tissue in high fat diet-fed mice
[65]. Numerous studies have focused specifically on the role of visceral adiposity in prostate
tumor growth and aggressiveness [234, 235]; however, the effects of bone marrow adiposity
and inflammation in tumor growth in bone are not well studied. Bone is a primary site of
metastasis of prostate cancer and obese men have a three-fold higher risk of progression to
metastatic disease compared to normal-weight men receiving the same treatment [236].
Emerging literature evidence suggests that conditions including obesity and inflammation,
known to disturb homeostasis in the bone microenvironment [35, 182], may be contributing
factors to colonization and growth of prostate tumors in the bone (reviewed in [42]).
Bone marrow macrophages (BMMs) are mediators of inflammatory processes suggested
to play distinct functions within tumor microenvironment [86, 237, 238]. In conjunction with
adipocytes, BMMs release various cytokines that can aid in tumor homing and growth at
metastatic sites such as bone. Two such inflammatory chemokines are CXCL1 and CXCL2 that
share 90% sequence homology and bind to the same G-protein coupled receptor, CXCR2 [131].
Both chemokines play a significant role in neutrophil recruitment during normal immune
response; however, they have also been linked to tumor growth and malignancy. A beautiful
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study conducted by Acharyya and colleagues demonstrated that CXCL1 and CXCL2 are amplified
in 20% of human metastatic breast tumors and knockdown of CXCL1 and CXCL2 in vivo reduced
tumor growth and the incidence of lung metastasis and relapse of metastatic lung tumors [131].
This was also functionally significant because tumor secretion of CXCL1 and CXCL2 activated
infiltrating myeloid cells to secrete calcium-binding proteins that protect tumor cells from
death, even after chemotherapy [131].

Others have shown that CXCL1 transcripts are

enhanced in stromal fibroblasts in aged mice and this supply of CXCL1 potentiates epithelial
proliferation of prostate tissue in benign prostatic hyperplasia [239]. Moreover, studies have
suggested that HFD-fed mice have increased circulation of CXCL1 and CXCL2 supplied by
epididymal fat resulting in increased tumor growth in vivo, enhanced incidence of lung and liver
metastases, and induced tumor invasion in vitro [240]. Our studies presented in Chapter 4
showed that both chemokines are highly secreted by bone marrow adipocytes and they directly
contribute to osteolysis in tumor progression. Studies have previously focused on CXCL1 and
CXCL2 derived from tumor cells directly to aid in cancer-associated inflammation [241, 242].
Only recently have stromal-supplied CXCL1 and CXCL2 been investigated in tumorigenesis,
particularly in prostate cancer [243]. Because CXCL1 and CXCL2 may have multiple effects on
the bone marrow microenvironment, this current study investigated other sources of these
chemokines and their roles in macrophage homing and tumor invasion.
Physical and paracrine interactions between tumor cells and their surrounding
environment can have effects on macrophages in the bone as well as other sites, particularly in
the context of macrophage phenotype. M1 macrophages are classically activated in response to
bacteria and other foreign invaders and release highly pro-inflammatory factors to activate the
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adaptive immune response [244]. M2 macrophages are either inactive or aid in wound healing
after tissue injury [244]. These two types of macrophages are predominantly characterized by
the cytokines and cell surface receptors they express. M1 macrophages express tumoricidal
chemokines and factors, such as IL-1β, IL-6, nitric oxide synthase (NOS), and reactive oxygen
species (ROS), while M2 macrophages produce arginase 1, CD163, IL-10 and the mannose
receptor CD206 among others [244-246].

Interestingly, macrophage phenotype can be

influenced by the factors secreted by the neighboring cells, including adipocytes. Resident
visceral adipocyte macrophages of lean individuals have more of an M2 phenotype while obese
individuals have an activated M1 phenotype, validating previous reports that obesity and
organs with high fat content have characteristics of chronic inflammatory state [247]. This may
prove to be a critical factor accounting for increased tumor aggressiveness in overweight and
obese individuals because the accumulation of immune cells can be a strong stimulator of
cancer progression by supporting angiogenesis and other changes to the tumor
microenvironment [248], particularly in bone [42].
In this study, we investigated the effects of prostate tumor cells and adipocyte-derived
factors on BMM-stimulated inflammation in bone. We have shown in Chapter 4 that that gene
expression of host-derived CXCL1 and CXCL2 is increased in tumor-bearing mice and even more
pronounced in HFD-fed mice. We also showed that adipocytes are a significant source of these
chemokines in bone (Figure 4.7). Here, we demonstrate that CXCL1 and CXCL2 are also
supplied by macrophages and that secretion and expression of these chemokines is increased in
Transwell co-culture with prostate cancer cells in the presence of conditioned media from bone
marrow adipocytes. We also show that BMMs are more invasive toward tumor- and adipocyte-
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secreted factors, and these effects are inhibited in the presence of blocking antibodies to CXCL1
and CXCL2. In addition, we demonstrate that CXCL1 and CXCL2 induce prostate tumor invasion
through reconstituted basement membrane. This present study also provides evidence that
paracrine factors released by prostate cancer cells and bone marrow adipocytes induce
expression of markers associated with a pro-tumorigenic M2 macrophage phenotype that may
drive tumor progression in bone. Together, our results reveal and new role of macrophages in
adipocyte- and tumor-driven inflammation in bone.
5.2 Results
5.2.1 Tumor and adipocyte-derived factors drive CXCL1 and CXCL2 expression in BMMs
Previous studies have shown that mesenchymal precursors [241, 249], the common
progenitor cell type of adipocytes or osteoblasts, tend to differentiate into adipocytes with
increased age resulting in more fatty marrow [250]. Interestingly, our studies demonstrated
that BMMs isolated from aged mice are more invasive through collagen I than macrophages
from younger mice, and these effects are more pronounced in the presence of adipocytederived factors, suggesting that bone marrow adipocytes may aid in inflammation in bone with
age [42]. With age, stromal components of the prostate increase expression of CXCL1 and
CXCL2 which contributes to chronic inflammation and benign prostatic hyperplasia [251];
however, the roles of these chemokines in tumor and macrophage invasion during adipocytedriven inflammation in bone have not been fully investigated.
We previously showed that adipocytes express and secrete CXCL1 and CXCL2. To
determine if CXCL1 and CXCL2 levels in BMMs cultured are affected by their interaction with
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prostate tumor cells especially in the presence of bone marrow adipocyte-derived factors we
utilized in vitro Transwell co-culture system of BMMs and PCa cells. As shown in Figure 5.1 A,
gene expression of CXCL1 was increased in BMMs exposed to adipocyte-conditioned medium.
The CXCL1 mRNA levels were also augmented by co-culture with PC3 cells with no additional
effects from simultaneous exposure to Adipo CM. Interestingly, contrary to clear modulation of
CXCL1 levels, expression of CXCL2 remained fairly unchanged.
CXCL1 and CXCL2 chemokines are rapidly secreted during inflammatory events, thus it is
important to note that their gene expression may not necessarily reflect the secreted levels. To
address this, we performed CXCL1 and CXCL2 ELISA analyses of media conditioned by BMMs
cultured alone or in co-culture with PC3 cells. Our data revealed that upon co-culture with PC3
cells BMMs secreted 6 fold more CXLC1 (134.7 pg/mL) compared to BMMs cultured alone
(22.77 pg/mL). BMMs secreted the highest levels of CXCL1 in the presence of Adipo CM (446
pg/mL) and the combined PC3-Adipo CM (1142 pg/mL) cultures (Figure 5.1 B), suggesting
BMMs secrete CXCL1 primarily in response to adipocyte-supplied factors. As shown in Figure
5.1 C, CXCL2 secretion was enhanced in BMMs treated with Adipo CM (36.96 pg/mL) and even
more with PCa cells (282.3 pg/mL). CXCL2 levels remained elevated when BMMs were cultured
with PC3 cells and Adipo CM (212.4 pg/mL), suggesting BMMs secrete CXCL2 in response to
paracrine interactions with PCa cells. Together, these data suggest that BMMs-secreted
inflammatory factors may differ depending on the externally supplied stimuli in the bone-tumor
microenvironment.
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5.2.2 CXCL1 and CXCL2 signaling promotes BMM invasion
CXCL1 and CXCL2 are normally secreted by macrophages and serve as potent neutrophil
chemoattractants during inflammation and injury [130]. Importantly, both tumor- and stromal
supplied CXCL1 and CXCL2 are implicated in tumor progression [130, 252]. Previous studies
have shown that astrocytes in the spinal cord secrete CXCL1 in response to increased bone
destruction associated with femoral prostate tumor growth, resulting in increased bone pain
and overexpression of CXCR2 in neurons [253]. Further evidence showed that ovarian cancer
cells overexpressing CXCR2 activate epidermal growth factor receptor-Akt pathway and
promote increased migration, invasion, growth, and colony formation in part by activation of
CXCL1 and CXCL2-mediated signaling [254].
Therefore, we examined the effects of CXCL1 and CXCL2 signaling in invasion of BMMs towards
tumor-derived factors. BMMs were cultured on collagen I and allowed to invade toward PC3
cells in the presence or absence of Adipo CM. BMMs were comparably invasive toward PC3
cells and Adipo CM and their invasive potential was further increased towards PC3 cells
cultured in the presence of Adipo CM (Figure 5.2). We next determined if CXCL1 and CXCL2 are
directly involved in promoting BMM invasion toward PC3 and adipocyte-derived factors by
blocking the activity of these ligands with neutralizing antibodies (Figure 5.3). We observed
that blocking either chemokine results in significant reduction of macrophage invasiveness
toward either tumor- or adipocyte-supplied factors (Figure 5.3, bottom left and middle
panels). Surprisingly, BMM invasion was not significantly affected by CXCL1 and CXCL2 blocking
antibodies when PC3 cells were cultured in the presence of Adipo CM (Figure 5.3, right panel).
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This suggests that the combination of PC3 cells and Adipo CM may be inducing the levels of
CXCL1 and CXCL2, thus reducing the sensitivity to blocking antibody treatment. Alternatively,
prostate tumor cells themselves may be affected by Adipo CM and produce additional factors
that induce macrophage invasion independent of CXCL1 and CXCL2 axis.
5.2.3 CXCL1 and CXCL2 promote invasion of prostate cancer cells in the absence of CXCR2
Our data presented thus far clearly indicate that gene expression of CXCL1 and CXCL2
are abundantly present in tibiae of HFD fed mice, especially under conditions of high marrow
adiposity. To assess whether in addition to their involvement in osteoclast and macrophage
function these chemokines may have any direct effects on tumor cells, we performed invasion
assays in the absence or presence of CXCL1 and CXCL2 recombinant proteins. As shown in
Figure 5.4, both chemokines stimulated invasion of PC3 cells through rBM. This suggests that
these ligands may be playing novel roles in tumor progression in bone by regulating both tumor
and macrophage invasion in the metastatic niche.
CXCR2, the common receptor shared by CXCL1 and CXCL2, is expressed in a variety of
cell types including fibroblasts, smooth muscle cells, and neutrophils [129]. Since CXCL1 and
CXCL2 are secreted by macrophages as well as bone marrow adipocytes in vitro, and both
appear to have an effect on tumor cell invasiveness, we investigated if adipocyte-supplied
CXCL1 and CXCL2 affect the expression of CXCR2 in prostate tumor cells. Surprisingly, despite
previously reported expression of CXCR2 in prostate cancer cells [146, 255, 256], we observed
almost undetectable levels of endogenous CXCR2 in PC3 cells cultured alone or with Adipo CM
(Figure 5.5).
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Because we did not detect the receptor in vitro, we assessed whether PC3 cells may
express CXCR2 in vivo. As shown in Figure 5.6 PC3 tumors grown intratibially expressed very
low or undetectable transcript levels of human CXCR2, result further confirming our in vitro
findings that PC3 cells do not express CXCR2. In fact, CXCR2 transcripts were also absent in
other prostate cell lines such as C4-2B and DU145 cells in the presence or absence of Adipo CM,
in contrast to primary human neutrophils (Table 5.1), which we used as a positive control [257].
These results suggest that CXCL1 and CXCL2 may bind other receptors on prostate tumor cells
to promote this invasive behavior.

Together, these data highlight the need for further

investigation of the endogenous expression of CXCR2 in prostate malignancy in order to better
understand how its ligands affect the bone-tumor microenvironment.
5.2.4 BMMs express markers of M2 phenotype in PC3-BMM co-culture
It is well documented that M2 macrophages promote tumor migration, invasion,
angiogenesis, and tumor growth [258, 259].

Therefore, we investigated whether the

interaction of BMMs with tumor cells in vitro and in vivo had any effect on their M1/M2
phenotype. Specifically, we assessed gene expression of the M1 marker nitric oxide synthase
(NOS2) and M2 markers arginase-1 (ARG1), IL-10, and CD163. PC3 and ARCaP(M) tumorbearing mice on LFD and HFD expressed high levels of M1 and M2 factors (Figure 5.7 A, B).
Most of these genes were further increased in HFD mice compared to LFD with the notable
exception of CD163 (Figure 5.7 B). To directly investigate tumor cell effects on phenotypic
switch, we assessed the expression of these genes in BMM-PCa co-culture in vitro (Figure 5.8).
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Interestingly, BMMs cultured with PC3 and ARCaP(M) cells expressed significant
amounts of ARG1, result in line with our in vivo findings. The M1 marker NOS2 was significantly
reduced, suggesting that paracrine signals from tumor cells may stimulate BMMs to reduce proinflammatory stimuli. The expression of M2 marker CD163 was enhanced in BMMs interacting
with tumor cells while surprisingly IL-10 cytokine expression was reduced.

We further

investigated why IL-10 expression may be reduced by assessing changes in expression of OPN, a
regulator of macrophage behavior and phenotype as well as a potent negative regulator of IL10 [151, 260]. As shown in Figure 5.9, OPN is increased both at the gene (Figure 5.9 A) and
protein (Figure 5.9 B) levels in BMMs cultured with PCa cells and these levels are maintained in
the presence of Adipo CM. Although we saw trends towards M2 macrophage phenotypic
switch in our co-culture system, more directed studies are needed to verify these findings.

79

80

5.3 Discussion
Chronic inflammation is a driving force that promotes tumor progression and
aggressiveness in several cancers and the various ways cancer cells hijack the immune system
have been an area of intense study [196]. Sustained inflammation has been attributed to
reduced metabolism resulting in delayed clearance of highly toxic chemotherapy agents and
cytotoxicity in normal tissue [261]. We and others have shown that tumor-driven inflammation
in bone is particularly detrimental, often leading to altered bone homeostasis, bone loss, and
pain [262, 263]. Moreover, studies suggested that obesity perpetuates an inflammatory tumor
microenvironment by enhancing nuclear factor kappa b (NFκB) activity in circulating
mononuclear cells. Specifically, increased circulation of free fatty acids reduced the expression
of IκB, an inhibitory protein of NFκB, in circulating mononuclear cells and this over activity
resulted in high circulating levels of NFκB target factors, such as migration inhibitor factor (MIF),
IL-6, TNF-α, and matrix metalloproteinase-9 [264].

Although the effects of systemic

inflammation on bone remodelling have been well characterized, its roles in tumor growth in
bone and the resulting changes in adipocyte-driven inflammation in bone have not been fully
explored.
Macrophages are a major source of CXCL1 and CXCL2 [265], and limited reports have
suggested that both chemokines are associated with tumorigenesis [239, 266]. Therefore, the
present study investigated the role of macrophage-driven inflammation in tumor behavior and
the effects of this interaction on macrophage phenotype. In chapter 4, we demonstrated that
CXCL1 and CXCL2 were highly increased in tumor-bearing tibiae of mice fed a high fat diet
compared to more modest changes in LFD mice. We also showed that bone marrow adipocytes
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secrete CXCL1 and CXCL2 to accelerate bone remodeling.

This is in line with our previous

findings demonstrating that inflammation is clearly enhanced in the bone tumor
microenvironment with increased marrow adiposity [43]. In the present study, we assessed the
effects of adipocyte-derived factors on macrophage-driven inflammation in metastatic bone
disease. Here we show specifically that BMMs are a source of CXCL1 and CXCL2 whose
secretion is enhanced in the presence of adipocyte- and PCa-derived factors, and the origin of
the stimuli determines how each chemokine is expressed. CXCL1 is highly secreted when
BMMs are cultured with bone marrow adipocyte-supplied factors compared to CXCL2stimulated expression primarily in BMM-PC3 co-culture conditions (Figure 5.1 B). This suggests
that although CXCL1 and CXCL2 share similar amino acid sequences, they may have different
functions in macrophage-driven inflammation in the bone tumor microenvironment.
The interactions between tumor cells and the surrounding stroma have received
increased attention as possible prognostic indicators of reduced survival. Clinical and in vitro
studies showed that macrophage infiltration into breast tumors results in increased disease
recurrence, mammosphere formation, tumor migration, and invasion demonstrating that
macrophages provide factors that aid in malignant progression [267, 268]. Further evidence
suggests that tumor cells attract macrophages by secreting a number of chemotactic factors,
namely monocyte chemotactic protein-1 (MCP-1), and monocyte colony stimulating factor (MCSF) [68]. Interestingly, adipocytes further promote these effects when they directly interact
with tumor cells and initiate homing of macrophages to adipocyte-rich areas of the surrounding
stroma [269]. In the present study, we demonstrated that bone marrow macrophages are
more invasive toward factors secreted by prostate tumor cells and adipocytes and this invasive
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behavior is even more pronounced when tumor cells are treated with Adipo CM (Figure 5.2),
effects that are blocked with neutralizing antibodies to CXCL1 and CXCL2 (Figure 5.3). Notably,
we observed no significant reduction in BMM invasion toward PC3 cells and Adipo CM in the
presence of CXCL1 and CXCL2 neutralizing antibodies, suggesting that other factors in addition
to CXCL1 and CXCL2 may stimulate these effects. These results provide evidence that
adipocytes, macrophages, and tumor cells work in concert to fuel tumor-associated
inflammation.
As previously mentioned, CXCL1 and CXCL2 have inflammatory as well as protumorigenic effects. CXCL1 is highly expressed in stromal fibroblasts surrounding breast tumors
and its overexpression is associated with increased tumor grade and overall poor prognosis
[270]. CXCL2 has been implicated as a survival factor secreted by primary bone marrow
mononuclear cells that stimulates chronic inflammation and protects lymphocytic leukemia
cells against apoptosis in vitro [271]. Interestingly, levels of CXCL1 and CXCL2 have been
reported to be highly enhanced in prostate stromal cells when stimulated with factors secreted
by newly transformed prostate epithelial cells, particularly Il-1β [243]. In vitro and in vivo
models of prostate cancer reported that CXCL1 and CXCL2 are involved in prostate tumor
migration and invasion [252, 272, 273]. However, contradictory to work previously published by
others [146, 255], we were unable to detect any significant mRNA levels of CXCR2 in any of the
tested prostate cancer cells both in vitro and in vivo (Figures 5.5-5.6 and Table 5.1). Notably,
our results appear to be in line with findings from a breast cancer model demonstrating that
breast cancer cells express and utilize CXCL1 and CXCL2 in tumor progression but have very low
transcript levels of CXCR2 [131, 274]. Together, this suggests that CXCL1 and CXCL2 may
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stimulate invasion by paracrine interactions with cell in the tumor microenvironment rather
than direct effects on tumor cells.
It is noteworthy that cells in the bone tumor microenvironment are known to be
versatile in response to changes in environmental stimuli, specifically macrophages [275, 276].
Phenotypic changes are a common occurrence when macrophages interact with tumor cells, as
a downstream effect of altered expression of proteases, surface receptors, and cytokines [74].
It is reasonable to speculate that monocytes may be induced by CXCL1 and CXCL2 supplied by
macrophages and adipocytes to differentiate into M2 macrophages that produce OPN to aid in
tumor progression [277] and bone remodeling [278]. This suggests that the roles and M1 and
M2 macrophage phenotypes of are more complex than previously thought.
Nonetheless, the traditionally recognized function of these macrophage subtypes in malignancy
has remained fairly consistent. An in vivo model of glioma was used to demonstrate a
disproportionate influx of M2 macrophages around and in the tumor and depletion of
macrophages using the macrophage Fas-induced apoptosis (MAFIA) transgenic mouse model,
showed greatly reduced tumor growth and angiogenesis [279]. This provides direct evidence
for negative impact of M2 macrophages on tumor promotion. Others have shown that
hyaluronan (HA), a matrix component found in most tissues such bone and breast, binds CD44
receptor on resting monocytes and drives their differentiation to an M2 phenotype while
inducing apoptosis in M1 macrophages [280]. Clinical evidence has since followed, directly
correlating M2 accumulation in breast tumors with levels of hyaluronan [281]. Many more
studies have also linked M2 accumulation with poor disease outcome [282, 283]. In the present
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study we investigated genes associated with M1 (NOS2) and M2 (CD163, ARG1, IL-10) and
showed that most of these genes were upregulated in tumor-bearing mice, particularly those
on HFD (Figure 5.7). Furthermore, we demonstrated that PC3 cells cultured with BMMs in vitro
tended to shift the marker expression in BMMs to a more M2 phenotype with the exception of
reduced IL-10 expression (Figure 5.8). We attributed this reduction in IL-10 levels to increased
expression of OPN, a modulator of macrophage inflammation and phenotype [163, 284], and a
negative regulator of IL-10 [151, 260] (Figure 5.11). Further studies are needed to determine if
BMM-supplied osteopontin directly contributes to macrophage phenotypic switch.
With the growing attention on the detrimental roles of macrophages in tumorigenesis,
numerous clinical trials are being conducted to investigate the effects of M1 versus M2
phenotype in disease prognosis and ways they can be targeted therapeutically. Notably, an
anti-macrophage migration inhibitory factor (MIF) antibody is currently being tested in a phase I
clinical trial in the treatment of solid tumors, particularly colon and rectal cancers, as the means
of reducing macrophage recruitment and preventing tumor growth [270]. Results of another
recently completed clinical trial examining the effects of administering recombinant GM-CSF to
newly diagnosed prostate cancer patients before radical prostatectomy in an attempt to boost
M1 macrophage activation and tumor-killing ability are currently pending [285]. If these
therapies successfully promote M1 activation at the tumor site, it would be interesting to
determine if levels of CXCL1 and CXCL2 are reduced with the presence of more M1
macrophages in the tumor milieu and how it may disrupt tumor growth, particularly in bone.
Based on previous reports and evidence provided herein, therapies targeting inflammation may
be

a

key

element

that

slows

tumor

growth

and

aggressiveness

in

bone.
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CHAPTER 6: BONE MARROW MACROPHAGE-DERIVED OPN PROMOTES PROSTATE TUMOR
INVASION AND SURVIVAL IN BONE
6.1 Introduction
Metastatic bone disease is devastating and incurable, often causing bone pain, fracture,
and reduced quality of life [211]. Patients with advanced prostate cancer commonly develop
drug resistance and 85–100% of patients who die of prostate carcinoma have some evidence of
bone metastases [286, 287]. Importantly, many complications associated with metastatic
disease arise because of underlying inflammation, which is known to aid in altered bone
remodeling, tumor colonization and invasion [66].

One cell type that mediates this

inflammation in bone are marrow macrophages, which are capable of secreting both pro- and
anti-inflammatory factors [288], recruiting tumor cells to the bone, and regulating the adaptive
immune response [289]. Because macrophages play central roles in inflammation, it is not
surprising that they may be a prime target of tumor cells to aid in progression, immune evasion,
and tolerance [289, 290].
The interactions between macrophages and tumor cells are very widely studied,
highlighting the importance of the stroma in malignancy [232, 237, 291].

For example,

macrophage colony-stimulating factor 1 (M-CSF1) is a key factor that promotes monocyte
recruitment and proliferation [292]. Previous studies have demonstrated that prostate cancer
cells treated with androgen deprivation therapy express high levels of M-CSF1 leading to
increased infiltration of macrophages into the tumor and eventual recurrence and these effects
are reduced in the presence of the CSF1 receptor inhibitor PLX3397 [82]. Another study
demonstrated that PC3 cells treated with docetaxel and co-cultured with macrophages showed
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increased production of several host-derived chemokines including IL-4, IL-6, and macrophage
inhibitory cytokine 1, all strongly correlated with progressive disease and reduced overall
survival in prostate cancer patients [293]. However, although there have been numerous
reports demonstrating the important role of macrophages in tumor recurrence and growth, few
studies to date have investigated the roles of bone marrow macrophages in tumor progression
in bone.
Several cell types in bone secrete osteopontin (OPN), a glycosylated bone protein
belonging to the SIBLING (small integrin-binding ligand N-linked glycoproteins) family and
involved in bone remodeling, insulin resistance, and inflammation (reviewed in [149]).
Osteopontin is particularly important in tumor-driven inflammation because it promotes
monocyte migration and regulates COX-2 and MCP-1 expression in tumor-associated
macrophages [156, 294]. OPN is also expressed in tumor cells and studies have suggested that
alternatively spliced isoforms OPNb and OPNc may have different functions in disease
progression of the breast, glioma, lung cancer, and prostate cancers [159]. OPN binds to
various receptors including αVβ1, 3, and 5, CD44 as well as its splice variants CD44v3 and v6
[295]. Recent attention has focused on the expression and roles of CD44v6 expression and
signaling in tumor invasion. CD44v6 expression is upregulated in ovarian cancer and drives
tumor adhesion, migration and invasion [296].

CD44 and CD44v6 expression were both

correlated with reduced patient survival in head and neck cancers [297]. αVβ3 expression has
also been linked to tumor progression because it plays a role in stimulating angiogenesis,
invasion and metastasis in solid tumors [298, 299]. Studies have investigated osteopontin
signaling in normal inflammatory and bone remodeling events [151]; however, the role of
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osteopontin in metastatic prostate cancer growth and progression in bone is not fully
understood.
We previously showed that osteopontin secretion is enhanced in macrophages cultured
with PCa cells (Figure 5.11). Therefore, in this part of our studies we investigated the role of
bone marrow macrophage-derived osteopontin, in tumor invasion and downstream signaling
through its receptors CD44, CD44v6, and αVβ3. Utilizing previously reported meta-analyses of
OPN gene transcript available in the Oncomine data bank, we show that OPN expression is
increased in metastatic prostate cancer tissues compared to primary prostate tissues. Using an
in vivo model of prostate tumor growth in bone, we show that OPN expression is increased in
PC3 and ARCaP(M) tumor-bearing mice and these levels are further augmented in mice fed
HFD. Utilizing in vitro Transwell co-culture system of PCa cells with BMMs, we also show that
BMMs express and secrete OPN in response to tumor cells. We further demonstrate that BMMderived factors, including osteopontin, promote prostate tumor invasion and blocking the
receptors CD44v6 and αVβ3 effectively inhibits tumor invasion toward BMMs. We also provide
evidence suggesting that invasive and proliferative effects observed are, in part, mediated by
activation of Akt pathway, and upregulation of anti-apoptotic factors Bcl2, Bcl-xL, and survivin.
We demonstrate that BMMs induce a hypoxic response in tumor cells as shown by increased
expression of hypoxia markers carbonic anhydrase IX and VEGF as well as ER stress factors BiP
and XBP-1, which are known mediators of stress response pathways associated with tumor cell
survival and disease progression [300, 301]. Collectively, our results highlight the importance of
tumor associated macrophages in metastatic disease and reveal a new mechanism of OPN
involvement in tumor survival and ER stress.
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6.2 Results
6.2.1 OPN is overexpressed in metastatic prostate cancer patients
Clinical evidence has suggested that gastric and lung cancer patients that express high
levels of OPN have a higher rate of disease recurrence and reduced overall survival following
chemotherapy or surgical resection, respectively [302, 303]. To determine if OPN expression is
upregulated with disease progression in prostate cancer, we searched the OncomineTM Gene
Browser for changes in mRNA expression between patients with localized versus metastatic
prostate cancer. Our analysis revealed that PCa patients with metastatic disease have over 70fold increase in osteopontin levels based on the Ramaswamy et al gene expression dataset
[304] (Figure 6.1 A) and over 12-fold increase based on Yu et al dataset [305] (Figure 6.1 B).
6.2.2 Host bone OPN expression is increased in vivo in tumor-bearing mice
Inflammation is one of the driving stimuli that promote tumor invasion and growth.
Previous studies have clearly demonstrated that tumor-associated macrophages secrete
significant levels of OPN at the tumor-stromal interface to promote progression of various
malignancies such as colon, pancreas, breast, lung, prostate, melanoma, and ovarian cancers
[306]. Therefore, we sought to determine if OPN expression is altered during prostate tumor
growth in bone. PC3 and ARCaP(M) tumors were established in bone by intratibial injection and
host OPN was assessed by Taqman RT-PCR analyses. Gene transcripts of OPN were significantly
elevated in both PC3- and ARCaP(M) tumor-bearing tibiae compared to PBS control (4.77 fold
increase in PC3 tumors and 2.48 fold increase for ARCaP(M) tumors) (Figure 6.2 A, B).
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Interestingly, increased OPN expression in macrophages has been implicated in
adipocyte-driven inflammation, promoting insulin resistance [156]. We observed that tumorbearing mice fed a high fat diet expressed significantly more OPN than low fat diet-fed mice
(Figure 6.2 C, D).
6.2.3 OPN expression is increased in macrophages cultured with prostate cancer cells
Several cell types in bone express OPN in addition to macrophages and they include
osteoclasts, osteoblasts, endothelial cells and natural killer cells [307]. To investigate the
changes in tumor-stimulated secretion of macrophage osteopontin, PC3 and ARCaP(M) cells
were co-cultured with BMMs. As shown in Figure 6.3, gene expression of OPN is enhanced in
macrophages in response to paracrine interactions with PCa cells (Figure 6.3 A, B). Since OPN
is largely a secreted protein, we assessed the protein expression of this glycoprotein in lysates
and media from BMM-PCa co-cultures. Mirroring RT-PCR analyses, osteopontin was robustly
secreted by BMMs co-cultured with PC3 and ARCaP(M) while intracellular levels were largely
unchanged (Figure 6.3 C).

These data suggest that prostate tumor cells promote the

production of BMM-supplied osteopontin to drive inflammatory events in the bone marrow
milieu.
6.2.4 CD44 expression is altered in prostate cancer cell lines
OPN can bind to several integrin receptors to mediate its downstream effects; however,
its primary receptors are CD44, CD44v6, and αVβ3 [308]. Importantly, studies have suggested
that increased CD44 expression in PC3 and DU145 cell lines is a marker of a stem-like
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phenotype in vitro [309, 310]. Therefore, we examined changes in these receptors in tumor
cells co-cultured with BMMs (Figure 6.4). Protein expression of CD44 was increased in both
PC3 and DU145 cells cultured with BMMs while levels of this receptor were reduced in
ARCaP(M) cells (Figure 6.4 A). Notably, endogenous, baseline protein expression of CD44 was
higher in ARCaP(M) cells compared to DU145 and PC3 cells, suggesting that the decline in
expression upon ligand stimulation might be a result of saturation and receptor degradation.
αVβ3 and CD44v6 protein expression remained unchanged; however, we observed that all
three PCa cell lines expressed high levels of both receptors even in the absence of BMMs
(Figure 6.4 B, C). We also assessed levels of CD44v6 and αVβ3 expression in tumor cells treated
with recombinant osteopontin protein by flow cytometry and we observed no significant
differences (Figure 6.5). Immunocytochemical analysis of CD44v6 also demonstrated that PC3
cells cultured with BMMs do not result in recycling or cytoplasmic accumulation of the receptor
(Figure 6.6).
6.2.5 Osteopontin promotes prostate tumor invasion
Tumor-derived OPN has been implicated as a driving factor of invasion and growth of
cancers of the breast, liver, lung, stomach, prostate, and colon [311] and more recently oral
squamous cell carcinoma [312]. Additional evidence has suggested that macrophage-secreted
OPN may be a negative predictive factor of survival in non-small cell lung cancer [313].
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To examine the effects of macrophage-supplied OPN in prostate tumor invasion, PC3
and ARCaP(M) cells were allowed to invade toward BMMs for 48 hours. Exposure to BMMderived factors promoted increased invasion of PCa cells through reconstituted basement
membrane-coated inserts (Figure 6.7 A, B). Given that several macrophage-supplied factors
other than OPN can promote invasiveness, we utilized blocking antibodies to the OPN receptor
integrin αVβ3.

Neutralization of the receptor effectively inhibited invasion of PC3 and

ARCaP(M) cells. We also observed a similar reduction in tumor cell invasion toward BMMs
when PC3 cells were treated with neutralizing antibodies to CD44v6 (Figure 6.7 C). To
investigate this more closely, we treated PC3 and ARCaP(M) cells with recombinant OPN
protein to directly assess the effects of OPN on tumor cell invasiveness. PC3 cells were
significantly more invasive in the presence of OPN (Figure 6.8 A); however, we observed a less
dramatic increase in invasiveness for ARCaP(M) cells (Figure 6.8 B).
To examine why this may be the case, we performed Taqman RT-PCR analyses of tumorderived OPN in both cell lines. Our results revealed that ARCaP(M) cells have much higher
baseline OPN levels (Ct value, 19.6912) than PC3 cells (Ct value, 35.6002) (Table 6.1). This
suggests that PCa cells that express higher levels of endogenous OPN are not as responsive to
externally supplied OPN and other factors secreted by BMMs may bind to the same receptor
and promote the observed invasive behavior. Together, these data suggest that blocking the
receptors for OPN partially inhibits invasion; however, other BMM-supplied ligands may
promote these effects as well.
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6.2.6 Akt and pro-survival factors are increased in prostate tumor cells cultured with BMMs
Akt activation has been well characterized as one of the key signaling mechanisms
involved in tumor migration, invasion, growth, enhanced tumor metabolism, chemoresistance
and survival [52, 314, 315]. Based on this evidence, we investigated the contribution of
paracrine interactions between BMMs and PCa cells to tumor survival (Figure 6.9). PC3 cells cocultured with BMMs showed increased phosphorylation of Akt and protein expression of
survival proteins Bcl-xL and survivin (Figure 6.9 A-C). Moreover, gene transcripts of Bcl-2 were
elevated while the pro-apoptotic marker Bax was moderately decreased (Figure 6.9 D), results
suggesting that BMMs secrete factors in the tumor microenvironment that act on prostate
tumor cells to promote survival. To directly assess the effects of BMM factors on tumor
survival, PC3 cells were pre-treated for 48 hours with docetaxel, a widely used chemotherapy
agent that stabilizes microtubules resulting in disruption of mitosis and apoptosis [316].
Following pre-treatment, PC3 cells were co-cultured with BMMs. As shown in Figure 6.9 E, Akt
phosphorylation was highly pronounced in PC3 cells that received docetaxel treatment and
exposed to BMMs, suggesting a possible role of BMMs in tumor survival.
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6.2.7 BMMs induce hypoxic response in tumor cells resulting in ER Stress
In addition to enhanced expression of classic pro-survival factors, evidence has
suggested that tumor cells utilize other mechanisms such as the hypoxia and ER stress response
pathways to thrive in the metastatic niche [317, 318]. To determine the effects of BMMs on
hypoxia and ER stress response, we assessed expression of hypoxia markers carbonic anhydrase
IX (CA9) and vascular endothelial growth factor (VEGF) as well as ER stress factors binding
immunoglobulin protein (BiP) and X-box binding protein 1 (XBP1). Notably, CA9 is a target gene
of hypoxia inducible factor 1α that is overexpressed in malignant tumors resulting in
metastasis, inflammation, and angiogenesis [319-321]. As shown in Figure 6.10, BMMs do
indeed induce a hypoxic response in PC3 cells as demonstrated by increased gene expression of
CA9 and VEGF (Figure 6.10 A). To determine if hypoxia in tumor cells is in part driven by BMMderived OPN, we cultured PC3 cells with BMMs isolated from OPN -/- mice (Figure 6.10 B).
Interestingly, CA9 was increased in tumor cells similarly to wild-type BMMs; however, VEGF
remained unchanged in PC3 cells cultured with OPN -/- BMMs. It is important to note that OPN
has been implicated as a potent positive regulator of VEGF, particularly in cancer progression
[294, 322, 323].
Given a previously reported link between hypoxia and ER stress pathways, we
investigated the effects of BMM-stimulated hypoxia in ER stress response in PC3 cells. Figure
6.10 C shows that BMM stimulate tumor cells to express robust amounts of intracellular BiP, a
heat shock chaperone protein that binds misfolded proteins and shuttles them for proteasome
degradation [324]. Although not as pronounced, BiP was also detected in the media,
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suggesting that BiP can be secreted by tumor cells and signal to other cells or serve in autocrine
signaling to further promote ER stress. A downstream factor of BiP is XBP1, a transcription
factor that is activated by alternative splicing by the type I transmembrane protein IRE1-α
expressed on the surface of the ER [325].Once activated, XBP1 can bind to promoter regions of
target genes associated with tumor survival, proliferation, and cell fate in hypoxic or stressed
conditions [320, 326-328]. Indeed, mRNA expression of both the full-length and spliced forms
of XBP-1 was increased in PC3 cells cultured with BMMs and these effects were further
enhanced under hypoxic conditions (Figure 6.10 D). These data suggest that BMMs simulate
hypoxia and ER stress in tumor cells and this is in part promoted by osteopontin.
6.2.8 Blocking αVβ3 and CD44v6 receptors on tumor cells inhibit pro-survival signaling
We next investigated the effects of blocking OPN signaling in prostate tumor cells using
neutralizing antibodies against αVβ3 and CD44v6. As expected, Akt phosphorylation was
increased in PC3 cells cultured with BMMs and a non-targeting IgG antibody had no effect on its
activation (Figure 6.11 A). Bcl-xL and BiP were also enhanced in co-culture, mirroring our
previous findings. In the presence of blocking antibodies to αVβ3 and CD44v6, both pAkt, BclxL, and BiP protein levels were reduced, suggesting that receptor-ligand interaction are
important to downstream activation of pro-survival and ER stress signaling cascades. We also
cultured PC3 cells with OPN -/- BMMs to determine if OPN has a direct role in PCa survival. We
observed and increase in Akt phosphorylation and Bcl-xL protein expression in PC3 cultured
with WT BMMs and levels were comparable in tumor cells cultured with OPN-/- BMMs (Figure
6.11 B). Gene expression of BCL2 remained unchanged in PC3 cells culture with OPN -/- BMMs;
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however, we did observe a moderate reduction in the pro-apoptotic gene Bax (Figure 6.11 C).
These data suggest that other ligands besides osteopontin may bind to CD44v6 and αVβ3 to
activate downstream pro-survival mechanisms to promote tumor malignancy in bone.
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Discussion
The rigid and hypoxic nature of bone requires that tumor cells find innovative ways to
change and utilize their surroundings to promote survival and expansion.

Tumor cells

particularly thrive on certain cytokines produced by macrophages to stimulate pathways
associated with survival, migration, and growth, and angiogenesis [329, 330]. Arising from
these findings, the present study investigated the effects of BMM-driven inflammation,
particularly macrophage-derived OPN, on tumor invasion, survival, and ER stress.

We

demonstrated that tumor growth in bone results in increased gene expression of host OPN
levels (Figure 6.2 A, B).

These results were in line with gene array meta-analysis data

demonstrating OPN is enhanced in patients with metastatic disease compared to patients with
localized disease (Figure 6.1). Strikingly, OPN expression was further elevated in tumor-bearing
mice fed a high fat diet (Figure 6.2 C and D). These results are validated by other groups that
reported OPN expression is correlated with chronic inflammation and insulin resistance in
obesity [156, 331]. We also showed that OPN is robustly secreted into media from BMM-PCa
co-cultures and these data mimicked gene expression analysis of BMMs cultured with tumor
cells (Figure 6.3).
The effects of OPN signaling via CD44, CD44v6, and αVβ3 and its effects on tumor
progression have been investigated in various cancer types; however, many of these studies
focused specifically on the role of tumor-derived OPN and less on the contribution of this
inflammatory regulator by stromal components to promote malignancy. Previous evidence has
shown that breast tumor cells that no longer express CD44 are less able to migrate, invade, and
proliferate, and receptor signaling to key migratory and proliferative pathways such as MAPK,
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focal adhesion kinase, c-Src, Akt, and JNK are disrupted [332]. Less is known about the effects
of targeting CD44v6 and αVβ3 in metastatic bone disease aside from limited reports linking
protein expression of these receptors with angiogenesis [333], invasion [334], and overall poor
prognosis [335, 336]. Our study demonstrated that protein expression of CD44 was increased
in PC3 and DU145, but reduced in ARCaP(M) cells cultured with BMMs (Figure 6.4 A), while
there were no changes in expression and localization of CD44v6 and αVβ3 (Figure 6.4-6.6). As
previously mentioned, CD44, CD44v6, and αVβ3 are associated with increased tumor invasion.
We showed that PCa cells were more invasive toward BMM-derived factors and blocking αVβ3
and CD44v6 reduced these effects (Figure 6.7).
Increased OPN expression has been implicated in tumor invasion. Recent studies have
shown that extracellular OPN can act on breast cancer cells to promote tumor invasion in part
by altering the density of actin cytoskeleton and reducing adhesion [337]. OPN reportedly has
similar effects on migration and invasiveness in gliomas [338] and hepatocellular carcinoma
[339]. Unfortunately, there are very few studies that have investigated the effects of exogenous
OPN in prostate cancer. Although one study demonstrated that overexpression of alternatively
spliced OPN promotes invasion in prostate [340], studies have not been conducted looking at
the role of macrophage-derived OPN in the context of bone metastasis and progression. Our
study is the first to show that PC3 and ARCaP(M) cells treated with recombinant OPN are more
invasive through reconstituted basement membrane, although we observed that PC3 cells are
more invasive than ARCaP(M) cells (Figure 6.8). Upon further investigation, our results showed
that ARCaP(M) cells express more endogenous OPN than PC3 cells (Table 6.1) which may
account for the differences in tumor response to extracellularly-supplied OPN. Moreover,
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these data suggest surrounding metastatic niche may alter the gene expression profile of
invading tumor cells to allow them to adapt to an environment that may or may not supply the
factors needed for tumor growth.
Tumor cells utilize external factors to activate signaling mechanisms such as Akt to drive
expression of survival factors. A comprehensive study conducted by Dai et al. demonstrated
that OPN signaling directly promotes phosphorylation of Akt and PI3K to promote tumor
migration and also upregulate downstream VEGF to promote angiogenesis and tube formation
of endothelial cells [155]. Importantly, they demonstrated that blocking OPN signaling using
neutralizing antibodies significantly abrogated vasculature formation, VEGF expression, and
reduced cell viability resulting from inactivation Akt and PI3K [155]. Blocking osteopontin
signaling also reduced expression of anti-apoptotic markers Bcl-xL and Bcl-2, and increased
expression of the pro-apoptotic marker Bax, events resulting in tumor cell death [341]. In line
with previously published findings, our results demonstrated that BMM-secreted factors
promote Akt phosphorylation, and increased expression of survival genes (Figure 6.9),
suggesting that secreted factors from macrophages promote survival of prostate tumor cells.
We specifically tested this theory by culturing BMMs with PC3 cells pre-treated with docetaxel
and observed that tumor cells expressed higher levels of pAKT in co-culture conditions
compared to cells grown alone (Figure 6.9 E). We also showed that pAkt and Bcl-XL were
reduced in the presence of neutralizing antibodies to CD44v6 and αVβ3 (Figure 6.11 A).
Together, these data add to the testament that tumor-associated macrophages can promote
tumor survival and possible chemoresistance.
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One of the key components of tumor growth in primary and metastatic sites alike, is the
ability to survive under harsh conditions including hypoxia, chemical onslaught, over-activated
immune response, and limited access to nutrients and growth factors [342]. An elegant study
from Chen and colleagues demonstrated that the ER stress marker XBP1 may directly interact
with HIF1α in the same transcriptional complex, even more so under hypoxic conditions [300].
Furthermore, depletion of XBP1 in triple-negative breast cancer cells resulted in reduced levels
of CD44 and VEGF expression as well as increase rate of disease recurrence following
chemotherapy [300]. Similar links between hypoxia-induced ER stress and VEGF have also be
reported by others [343]; however, this link has not been investigated in prostate cancer,
especially at the level of metastatic bone disease. In the present study, we provide evidence to
suggest that BMMs promote both hypoxic and ER stress response in PCa cells and this is evident
by increased XBP1 splicing and protein expression of BiP in tumor cells cultured with BMMs
(Figure 6.10 C and D). To our knowledge, this is the first study to demonstrate that BMMs can
induce hypoxia and ER stress in prostate cancer.
Future studies are currently underway to further investigate the role of BMM-supplied
OPN in tumor invasion and survival. However, we must also consider the compensatory
mechanisms used by tumor cells in the absence of external sources of OPN. This glycoprotein is
expressed in prostate cancer cell lines [165, 344], so it is possible that endogenous levels in
tumor cells could be enhanced, particularly under hypoxic conditions or in response to chemical
induction. Moreover, BMMs lacking OPN may compensate for this loss and enhance other
factors that may serve a similar purpose of supporting malignant progression. Additional
studies are also needed to determine if BMMs lacking OPN have impaired ability to switch to
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M2 phenotype in the presence of tumor-derived factors and if this phenotype can be rescued
with exogenous OPN from the tumor. More in depth characterization of OPN null macrophages
is needed to determine the role of this protein in inflammation and tumor invasion.
This work features the multiple roles of bone marrow-derived macrophages in tumor
progression, survival, and invasion. Particularly, we highlight the effects of macrophagesupplied OPN in downstream signaling pathways in tumor cells via ligand bind on CD44v6 and
αVβ3 to promote tumor invasion in bone. To date, inhibitors or antibodies targeting OPN, CD44
or its variants, and integrin receptor αVβ3 have not been evaluated. Targeting them may prove
difficult because OPN and its receptors play roles in normal bone remodeling, metabolism, and
inflammation [149, 345]. However, based on our previous reports on macrophage involvement
in tumor metastasis [238], it may be feasible to design new therapies that specifically target
tumor-associated macrophages. Several clinical trials have been designed to determine the
clinical ramifications of macrophage infiltration to the tumor site and find feasible drug targets
that may slow prostate cancer progression [346, 347]. It remains to be determined if these will
be effective and further studies are needed to understand how the bone marrow niche
contributes to malignant progression in an effort to reduce or eliminate the incidence of
metastatic disease.
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CHAPTER 7: DISCUSSION AND FUTURE DIRECTIONS
Obesity contributes to several chronic diseases including diabetes, hypertension, and
atherosclerosis [348]. Obesity and the inflammatory state have also been directly correlated
with cancer initiation, progression, and metastasis [349]. Inflammatory cells and mediators are
present in the microenvironment of most tumors regardless of the site of origin [233].
Inflammation is also relevant in prostate cancer due to its tendency to metastasize to the bone
and promote the over activation of genes associated with wound healing response that is never
resolved [350]. Obesity-driven inflammation is closely associated with reduced overall patient
survival and increased tumor aggressiveness [351]. Most studies to date have focused on
linking BMI and general obesity with systemic effects on cancer risk and progression, but little is
known about local effects of bone marrow adiposity in metastatic prostate cancer.
The studies presented here sought to uncover molecular mechanisms involved in
interactions between prostate tumor cells, bone marrow macrophages, and adipocyte-supplied
factors in promoting the inflammatory environment and driving tumor progression in bone.
We demonstrate that macrophages are very invasive toward factors released by bone marrow
adipocytes and tumor cells and these same factors promote BMMs to secrete inflammatory
mediators that can in turn affect the tumor cells. Our studies specifically focused on CXCL1 and
CXCL2, chemokines with previously reported overlapping functions in tumor invasion and
survival, especially when endogenously expressed and secreted by tumor cells, such as in
ovarian, endometrial, oral squamous cell, and prostate cancers [207, 219, 256]. We provided
new evidence that stroma-supplied CXCL1 and CXCL2 are abundantly produced in bone and are
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just as important in metastatic progression as tumor-derived CXCL1 and CXCL2.
Fibroblasts and macrophages have been reported to be sources of CXCL1 and CXCL2 and
infiltrating tumor cells have been shown to stimulate their secretion to aid in tumor cell seeding
during early stages of cancer development, maintenance of a chronic inflammatory state, and
angiogenesis [8, 243, 352, 353]. In line with these previous findings, we show that bone
marrow macrophages are more invasive and secrete CXCL1 and CXCL2 in response to
adipocyte- versus tumor-derived factors. Additional studies may be necessary to determine the
specific factors secreted by prostate cancer cells and adipocytes to drive the abundant release
of CXCL1 and CXCL2 from macrophages. This may offer clues concerning the specific need
tumor cells may have for each chemokine since the CXCR2 receptor is not detectable in
prostate cancer cell lines in vitro.
It was previously thought that CXCL1 and CXCL2 serve solely as chemotactic factors for
neutrophils and tumor cells. Here we highlight a new function of these chemokines as key
factors involved in marrow adiposity-directed bone remodeling. We show that adipocytesupplied

factors

drive

RANKL/M-CSF

stimulated

osteoclastogenesis,

and

the

CXCL1/CXCL2/CXCR2 signaling axis is directly involved in osteoclast maturation of precursor
cells. This is in line with recent findings that pre-osteoclasts treated with lipopolysaccharide
produce CXCL1 and CXCL2 and both chemokines directly promote osteoclastogenesis [208,
243]. The data herein reveal a potential pathway utilized by bone marrow adipocytes to alter
bone remodeling events in the skeleton that are commonly associated with osteoporosis and
tumor metastasis.
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Notably, CXCL1 and CXCL2 are not the only ligands capable of binding CXCR2. CXCL3, 5,
6, 7, and 8 all have ELR motifs and bind CXCR2 with varying affinities [354]. It is currently
unknown if these factors act similarly to CXCL1 and CXCL2 and if bone marrow adipocytes
secrete these ligands. Notably, interleukin-8 (CXCL8), a human homolog of murine CXCL1 and
CXCL2, is secreted by cancer cells and also stimulates osteoclastogenesis [355, 356]. Thus, it is
probable that tumor-secreted factors in bone act in concert with adipocytes and macrophages
to accelerate bone remodeling, which may explain why we observed extensive bone
destruction in tumor-bearing mice fed HFD. CXCL1 and CXCL2 knock-out mice may be needed
to specifically elucidate the roles of each chemokine in normal bone remodeling to determine
the mechanisms used by bone-trophic tumors to further enhance osteoclast differentiation via
these factors. Although there have been no reports investigating these chemokines in bone
abnormalities in vivo, studies in CXCR2 knock-out mice have provided some clues concerning
the role of these chemokines in bone. Mice lacking CXCR2 are smaller and weigh less than wild
type mice [357]. Interestingly, femoral, tibial, and lumbar bone mineral density, and blood
vascularization in bone are reduced in CXCR2 null mice [357]. The observed skeletal differences
in CXCR2 null mice suggest important functions for this receptor in normal bone remodeling
and prompt further investigation of this signaling mechanism in bone-related disease.
Inflammation in the tumor environment is often a double-edged sword because
macrophages and other inflammatory cells can have both tumoricidal and tumorigenic
capacities. In some cases, tumor-associated macrophages have been shown to be highly proinflammatory and to secrete factors that induce homing of T cells to the tumor site [358]. This
was shown to result in apoptosis and reduced proliferation of colorectal tumors [358]. Similar

116

protective effects have also been reported in stomach cancers and melanomas [359]. However,
majority of literature evidence links tumor-associated macrophages with overall poor prognosis
in several cancers [359]. The present study demonstrated that resident macrophages and
adipocytes supply CXCL1 and CXCL2 to promote inflammation, bone remodeling, and tumor
invasion. In addition to CXCL1 and CXCL2, tumor-associated macrophages produce other
inflammatory mediators, such as osteopontin, to aid in tumor progression.
In addition to its roles in macrophage function and differentiation [149, 360],
osteopontin prevents apoptosis and promotes anchorage-independent growth in tumor cells
[311]. We show that osteopontin is highly expressed in vivo and particularly secreted in PCaBMM co-cultures in vitro. Notably, we also show that osteopontin and other macrophagesupplied factors enhance tumor invasion and seem to have effects on tumor survival by
mediating hypoxia, ER stress, and Akt-driven expression of pro-survival factors. In fact, it has
been demonstrated that osteopontin activates downstream targets of αVβ3 such as HIF1α to
promote hypoxia in tumors [361]. These findings may be clinically relevant because hypoxic
tumors are much less responsive to classic chemotherapies and have overall poor prognosis
[318]. Bone marrow macrophages may prove to be an important mediator of tumor survival
and progression as they may be ‘priming’ tumor cells via osteopontin signaling to turn on ER
stress and hypoxia response and thrive in bone. This is evident by the reported in vitro
investigations demonstrating that tumor cells treated with osteopontin demonstrate increased
survival under hypoxic conditions and are protected against phagocytosis by activated
tumoricidal macrophages [362]. Combined with current reports that hypoxia stimulates tumor
cell survival [363], M2 phenotype [355], and osteopontin overexpression [278], these events
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may all cooperate to drive more aggressive tumors in bone.
Because some cancers have a more positive outcome when macrophages are present, it
begs the question: how can macrophages in the bone tumor microenvironment be re-trained to
target cancer cells, especially when tumor expresses the same antigens as the host? This
complex question represents a central focus of the field of immunotherapy. Pre-clinical and
clinical trials have attempted to train the innate immune system to target tumor cells directly
and promote a strong immune response in dormant M2 macrophages [364-366]. Using in vitro
and in vivo bone xenograft models of multiple myeloma, studies have demonstrated that bone
marrow macrophages effectively phagocytose tumor cells treated with blocking antibodies to
CD47, an integrin surface receptor overexpressed in this tumor type [367]. However, the data
provided in these published studies do not address the possible contributions of hypoxia,
adipokines, and cytokines that may counteract these therapeutic strategies and prevent
macrophage reprogramming.
Our current work features the involvement of CXCL1/2/CXCR2 and osteopontin signaling
axes in bone remodeling, inflammation, and tumor invasion. This suggests that a single drug
may not be able to effectively reduce the tumor-promoting effects of the supporting stroma.
Activating an anti-tumor inflammatory response in addition to chemotherapy targeting the
tumor cells may be a more effective option in severing the ties that tumors have literally grown
to rely on.
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Prostate cancer (PCa) is the second leading cause of cancer-related deaths among men.
Evidence suggests that age and obesity, conditions associated with adipocyte accumulation in
the bone marrow, are linked to increased risk of developing PCa and progressing to metastatic
disease. Studies presented in this dissertation were based on the hypothesis that metastatic
progression in bone is a result of a cooperative effort between bone marrow adipocytes,
macrophages, osteoclasts, and PCa cells. We specifically focused on two adipocyte-supplied
chemokines, CXCL1 and CXCL2, and bone marrow macrophage-secreted osteopontin as key
drivers of pro-inflammatory environment in the bone marrow and important regulators of
tumor growth and survival in bone.
Our results revealed that adipocyte-supplied CXCL1 and CXCL2 are significant contributors to
tumor-driven osteolysis in metastatic disease. We showed that interaction of CXCL1 and CXCL2
with their receptor CXCR2 on osteoclast precursor cells drives osteoclastogenesis in vitro and
bone degradation in vivo. Our studies also demonstrated that in addition to its effects on
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osteoclasts, CXCR2 signaling axis is important for macrophage phenotype and function.
Specifically, blocking the CXCR2 interaction with its ligands reduces macrophage invasiveness.
We also showed that interaction of PCa cells with bone marrow macrophages in vitro and in vivo
promotes phenotypic switch towards more pro-tumorigenic phenotype. Importantly, we were
able to show that upon exposure to tumor cells macrophages secrete significant levels of
osteopontin, powerful pro-inflammatory protein that contributes to tumor growth and survival
in the bone metastatic niche. Collectively, our studies unravelled new mechanisms behind
metastatic PCa progression in bone. This work will serve as basis for future studies towards
discovering novel therapeutic targets for treatment of this incurable disease.
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